3M (MMM) 10-Q 26 Jul 24 2024 Q2 Quarterly report Financial data

Cover

Cover	6 Months Ended
	Jun. 30, 2024 shares
Document Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	1-3285
Entity Registrant Name	3M COMPANY
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-0417775
Entity Address, Address Line One	3M Center
Entity Address, City or Town	St. Paul
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55144-1000
City Area Code	651
Local Phone Number	733-1110
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	549,353,621
Entity Central Index Key	0000066740
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Common Stock, Par Value $.01 Per Share | New York Stock Exchange
Document Information
Title of 12(b) Security	Common Stock, Par Value $.01 Per Share
Trading Symbol	MMM
Security Exchange Name	NYSE
Common Stock, Par Value $.01 Per Share | Chicago Stock Exchange, Inc.
Document Information
Title of 12(b) Security	Common Stock, Par Value $.01 Per Share
Trading Symbol	MMM
Security Exchange Name	CHX
1.500% Notes due 2026 | New York Stock Exchange
Document Information
Title of 12(b) Security	1.500% Notes due 2026
Trading Symbol	MMM26
Security Exchange Name	NYSE
1.750% Notes due 2030 | New York Stock Exchange
Document Information
Title of 12(b) Security	1.750% Notes due 2030
Trading Symbol	MMM30
Security Exchange Name	NYSE
1.500% Notes due 2031 | New York Stock Exchange
Document Information
Title of 12(b) Security	1.500% Notes due 2031
Trading Symbol	MMM31
Security Exchange Name	NYSE

Consolidated Statement of Incom

Consolidated Statement of Income (Loss) (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Net sales	$ 6,255	$ 6,283	$ 12,271	$ 12,338
Operating expenses
Cost of sales	3,571	3,728	7,056	7,472
Selling, general and administrative expenses	1,132	11,615	2,260	12,763
Research, development and related expenses	280	298	534	595
Total operating expenses	4,983	15,641	9,850	20,830
Operating income (loss)	1,272	(9,358)	2,421	(8,492)
Other expense (income), net	(138)	72	82	128
Income (loss) from continuing operations before income taxes	1,410	(9,430)	2,339	(8,620)
Provision (benefit) for income taxes	203	(2,261)	423	(2,116)
Income (loss) from continuing operations of consolidated group	1,207	(7,169)	1,916	(6,504)
Income (loss) from unconsolidated subsidiaries, net of taxes	3	3	4	5
Net income (loss) from continuing operations including noncontrolling interest	1,210	(7,166)	1,920	(6,499)
Less: Net income (loss) attributable to noncontrolling interest	6	5	11	10
Net income (loss) from continuing operations attributable to 3M	1,204	(7,171)	1,909	(6,509)
Net income (loss) from discontinued operations, net of taxes	(59)	330	164	644
Net income (loss) attributable to 3M	$ 1,145	$ (6,841)	$ 2,073	$ (5,865)
Weighted average 3M common shares outstanding - basic (in shares)	553.8	553.9	554.4	553.3
Earnings (loss) per share from continuing operations — basic (in dollars per share)	$ 2.17	$ (12.94)	$ 3.44	$ (11.76)
Earnings (loss) per share from discontinued operations — basic (in dollars per share)	(0.10)	0.59	0.30	1.16
Earnings (loss) per share — basic (in dollars per share)	$ 2.07	$ (12.35)	$ 3.74	$ (10.60)
Weighted average 3M common shares outstanding - diluted (in shares)	554.8	553.9	555.3	553.3
Earnings (loss) per share from continuing operations — diluted (in dollars per share)	$ 2.17	$ (12.94)	$ 3.44	$ (11.76)
Earnings (loss) per share from discontinued operations — diluted (in dollars per share)	(0.10)	0.59	0.29	1.16
Earnings (loss) per share — diluted (in dollars per share)	$ 2.07	$ (12.35)	$ 3.73	$ (10.60)

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024		Jun. 30, 2023
Statement of Comprehensive Income [Abstract]
Net income (loss) attributable to 3M	$ 1,145	$ (6,841)	$ 2,073		$ (5,865)
Net income (loss) attributable to noncontrolling interest	6	5	11		10
Net income (loss) from continuing operations including noncontrolling interest	1,151	(6,836)	2,084	[1]	(5,855)	[1]
Other comprehensive income (loss), net of tax:
Cumulative translation adjustment	(145)	25	(353)		141
Defined benefit pension and postretirement plans adjustment	826	50	961		101
Cash flow hedging instruments	(7)	23	19		(1)
Total other comprehensive income (loss), net of tax	674	98	627		241
Comprehensive income (loss) including noncontrolling interest	1,825	(6,738)	2,711		(5,614)
Comprehensive (income) loss attributable to noncontrolling interest	(5)	(6)	(11)		(11)
Comprehensive income (loss) attributable to 3M	$ 1,820	$ (6,744)	$ 2,700		$ (5,625)
[1] The Consolidated Statements of Cash Flows include the results of continuing and discontinued operations and, therefore, also include cash and cash equivalents associated with Solventum through its April 2024 separation from 3M that were presented in current assets of discontinued operations in the 3M Consolidated Balance Sheet.

Consolidated Balance Sheet (Una

Consolidated Balance Sheet (Unaudited) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 10,083	$ 5,735
Marketable securities — current	255	50
Accounts receivable — net of allowances of $64 and $62	3,575	3,601
Inventories
Finished goods	1,956	1,842
Work in process	1,193	1,242
Raw materials and supplies	911	860
Total inventories	4,060	3,944
Prepaids	444	344
Other current assets	1,098	326
Current assets of discontinued operations	0	2,379
Total current assets	19,515	16,379
Property, plant and equipment	23,278	23,494
Less: Accumulated depreciation	(15,806)	(15,804)
Property, plant and equipment — net	7,472	7,690
Operating lease right of use assets	610	657
Goodwill	6,318	6,382
Intangible assets — net	1,266	1,323
Other assets	8,196	6,806
Non-current assets of discontinued operations	0	11,343
Total assets	43,377	50,580
Current liabilities
Short-term borrowings and current portion of long-term debt	1,302	2,947
Accounts payable	2,813	2,776
Accrued payroll	602	695
Accrued income taxes	407	304
Operating lease liabilities — current	169	192
Other current liabilities	9,052	6,660
Current liabilities of discontinued operations	0	1,723
Total current liabilities	14,345	15,297
Long-term debt	11,781	13,088
Pension and postretirement benefits	1,717	2,156
Operating lease liabilities	443	464
Other liabilities	11,103	14,021
Non-current liabilities of discontinued operations	0	686
Total liabilities	39,389	45,712
Commitments and contingencies
3M Company shareholders’ equity:
Common stock	9	9
Additional paid-in capital	7,146	6,956
Retained earnings	35,475	37,479
Treasury stock, at cost:	(33,147)	(32,859)
Accumulated other comprehensive income (loss)	(5,567)	(6,778)
Total 3M Company shareholders’ equity	3,916	4,807
Noncontrolling interest	72	61
Total equity	3,988	4,868
Total liabilities and equity	$ 43,377	$ 50,580

Consolidated Balance Sheet (U_2

Consolidated Balance Sheet (Unaudited) (Parenthetical) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Current assets
Allowances for doubtful accounts receivable	$ 64	$ 62
3M Company shareholders’ equity:
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, issued (in shares)	944,033,056	944,033,056
Common stock, outstanding (in shares)	549,353,621	552,581,136
Treasury stock (in shares)	394,679,435	391,451,920

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (Unaudited) - USD ($) $ in Millions		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Cash Flows from Operating Activities
Net income (loss) including noncontrolling interest	[1]	$ 2,084	$ (5,855)
Adjustments to reconcile net income (loss) including noncontrolling interest to net cash provided by operating activities
Depreciation and amortization	[1]	731	915
Company pension and postretirement contributions	[1]	(86)	(57)
Company pension and postretirement expense	[1]	898	75
Stock-based compensation expense	[1]	200	176
Deferred income taxes	[1]	115	(2,547)
Changes in assets and liabilities
Accounts receivable	[1]	(219)	(393)
Inventories	[1]	(270)	101
Accounts payable	[1]	166	135
Accrued income taxes (current and long-term)	[1]	(172)	(409)
Other — net	[1]	(1,659)	10,643
Net cash provided by (used in) operating activities	[1]	1,788	2,784
Cash Flows from Investing Activities
Purchases of property, plant and equipment (PP&E)	[1]	(644)	(852)
Proceeds from sale of PP&E and other assets	[1]	53	23
Purchases of marketable securities and investments	[1]	(943)	(775)
Proceeds from maturities and sale of marketable securities and investments	[1]	707	945
Other — net	[1]	(29)	40
Net cash provided by (used in) investing activities	[1]	(856)	(619)
Cash Flows from Financing Activities
Change in short-term debt — net	[1]	(205)	651
Repayment of debt (maturities greater than 90 days)	[1]	(2,653)	(1,802)
Proceeds from debt (maturities greater than 90 days)	[1]	8,367	1,107
Purchases of treasury stock	[1]	(421)	(29)
Proceeds from issuance of treasury stock pursuant to stock option and benefit plans	[1]	30	218
Dividends paid to shareholders	[1]	(1,221)	(1,655)
Cash transferred to Solventum related to separation, net	[1]	(577)	0
Other — net	[1]	(57)	(9)
Net cash provided by (used in) financing activities	[1]	3,263	(1,519)
Effect of exchange rate changes on cash and cash equivalents	[1]	(45)	(43)
Net increase (decrease) in cash and cash equivalents	[1]	4,150	603
Cash and cash equivalents at beginning of year	[1]	5,933	3,655
Cash and cash equivalents at end of period	[1]	$ 10,083	$ 4,258
[1] The Consolidated Statements of Cash Flows include the results of continuing and discontinued operations and, therefore, also include cash and cash equivalents associated with Solventum through its April 2024 separation from 3M that were presented in current assets of discontinued operations in the 3M Consolidated Balance Sheet.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Significant Accounting Policies	NOTE 1. Significant Accounting Policies Basis of Presentation: The interim consolidated financial statements are unaudited but, in the opinion of management, reflect all adjustments necessary for a fair statement of the Company’s consolidated financial position, results of operations and cash flows for the periods presented. These adjustments consist of normal, recurring items. The results of operations for any interim period are not necessarily indicative of results for the full year. The interim consolidated financial statements and notes are presented as permitted by the requirements for Quarterly Reports on Form 10-Q. This Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and notes included in its Annual Report on Form 10-K. Certain amounts in prior periods’ consolidated financial statements have been reclassified to conform to current period presentation. Information provided herein reflects the impact of these changes for all applicable periods presented. • As discussed in Note 2, on April 1, 2024, 3M completed the previously announced separation of its Health Care business (the Separation) through a pro rata distribution of 80.1% of the outstanding shares of Solventum Corporation (Solventum) to 3M stockholders. As a result of the Separation, Solventum became an independent public company and 3M no longer consolidates Solventum into 3M’s financial results. In connection with the Separation, the historical net income of Solventum and applicable assets and liabilities included in the Separation are reported in 3M's consolidated financial statements as discontinued operations. • 3M made certain changes to the composition of segment information reviewed by 3M's chief operating decision maker (CODM) effective in the second quarter of 2024 largely as a result of the separation of Solventum and changes within its business segments effective in the first quarter of 2024 as further described in Note 19. To the extent these changes impacted 3M's disclosed disaggregated revenue information, data in Note 3 has also been updated. New Accounting Pronouncements: Refer to Note 1 to the Consolidated Financial Statements in 3M's 2023 Annual Report on Form 10-K for a discussion of applicable standards issued and not yet adopted by 3M. Relevant New Standards Issued Subsequent to Most Recent Annual Report In March 2024, the SEC adopted rules under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors , which require a registrant to disclose information in annual reports and registration statements about climate-related risks that are reasonably likely to have a material impact on its business, results of operations, or financial condition. The information would include disclosure of a registrant's greenhouse gas emissions. In addition, certain disclosures related to severe weather events and other natural conditions will be required in a registrant’s audited financial statements. Annual disclosure requirements would be effective for 3M as early as the fiscal year beginning January 1, 2025. However, in April 2024, the SEC voluntarily stayed the final rules pending certain legal challenges. The Company is evaluating the impact of these rules on its disclosures.

Discontinued Operations

Discontinued Operations	6 Months Ended
	Jun. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	NOTE 2. Discontinued Operations On April 1, 2024, 3M completed the previously announced separation of its Health Care business (the Separation) through a pro rata distribution of 80.1% of the outstanding shares of Solventum Corporation (Solventum) to 3M stockholders. The spin-off transaction was intended to be tax-free for U.S. federal income tax purposes. To reflect the completion of the spin, 3M recorded a decrease in shareholders equity for the net book value of applicable assets and liabilities included in the Separation, net of the book value of 3M's retained ownership. As a result of the Separation, Solventum became an independent public company and 3M no longer consolidates Solventum into 3M’s financial results. In connection with the Separation, the historical net income of Solventum and applicable assets and liabilities included in the Separation are reported in 3M's consolidated financial statements as discontinued operations. Following the Separation, as 3M no longer controls or has the ability to exert significant influence over Solventum, 3M measures, at fair value on a recurring basis, its retained ownership interest in Solventum common stock (see additional information in Note 7). 3M expects to monetize its stake in Solventum over time. The Company entered into various agreements to effect the Separation and provide for the relationship between 3M and Solventum, including, among others, a separation and distribution agreement; a tax matters agreement; and transition service, distribution, and contract manufacturing agreements; as well as certain commercial supply agreements. The transition service and distribution agreements have overall terms of two years following the Separation and each may be extended an additional year. The transition contract manufacturing agreement's term is three years with an ability to extend under certain circumstances. Supply agreements, by which each company may provide product to the other, have initial three-year terms, but may extend for particular products up to ten 3M continuing involvement with Solventum in the form of net sales under supply agreements and income from transition agreements is reflected in amounts disclosed in Note 19 relative to "Corporate and Unallocated" (recorded as net sales and associated costs) and "Other" (recorded as a direct offset to associated costs), respectively. Solventum transition agreement income for the three months ended June 30, 2024 included in "Other" was approximately $30 million (approximately $200 million gross fees, net of assigned costs). Transition services or purchases from Solventum are not material to 3M. Amounts due from Solventum and amounts due to Solventum under the agreements described above were approximately $0.5 billion and $0.2 billion, respectively, as of June 30, 2024. Information regarding net income (loss) from discontinued operations, net of taxes includes the following: Three months ended Six months ended Net Income (Loss) from Discontinued Operations, Net of Taxes (millions) 2024 2023 2024 2023 Net sales $ — $ 2,042 $ 1,987 $ 4,018 Cost of sales — 878 844 1,747 Other operating expenses 46 764 837 1,496 Other expense (income), net — (7) 44 (11) Income (loss) from discontinued operations before income taxes (46) 407 262 786 Provision for income taxes 13 77 98 142 Net income (loss) from discontinued operations, net of taxes $ (59) $ 330 $ 164 $ 644 Major classes of assets and liabilities of discontinued operations include the following: Assets and Liabilities of Discontinued Operations (millions) December 31, 2023 Assets Cash and cash equivalents $ 198 Marketable securities — current 3 Accounts receivable — net 1,149 Inventories 878 Other current assets 151 Current assets of discontinued operations 2,379 Property, plant and equipment — net 1,469 Operating lease right of use assets 102 Goodwill 6,545 Intangible assets — net 2,903 Other assets 324 Non-current assets of discontinued operations 11,343 Liabilities Accounts payable 469 Accrued payroll 209 Accrued income taxes 61 Operating lease liabilities — current 33 Other current liabilities 951 Current liabilities of discontinued operations 1,723 Pension and postretirement benefits 315 Operating lease liabilities 70 Other liabilities 301 Non-current liabilities of discontinued operations 686 Cash flows related to discontinued operations have not been segregated, and are included in the Consolidated Statement of Cash Flows for all periods presented. Selected financial information related to cash flows from discontinued operations is below. Six months ended Selected Cash Flows from Discontinued Operations (millions) 2024 2023 Depreciation and amortization $ 139 $ 277 Purchases of property, plant and equipment (PP&E) 77 104

Revenue

Revenue	6 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenue	NOTE 3. Revenue Disaggregated Revenue Information: The Company views the following disaggregated disclosures as useful to understanding the composition of revenue recognized during the respective reporting periods: Three months ended Six months ended Net Sales by Division (millions) 2024 2023 2024 2023 Abrasives $ 324 $ 334 $ 652 $ 675 Automotive Aftermarket 304 305 610 617 Electrical Markets 325 329 636 653 Industrial Adhesives and Tapes 531 517 1,049 1,033 Industrial Specialties Division 285 298 569 606 Personal Safety 857 849 1,714 1,717 Roofing Granules 133 133 261 243 Total Safety and Industrial Business Segment 2,759 2,765 5,491 5,544 Advanced Materials 244 305 507 606 Automotive and Aerospace 481 477 987 939 Commercial Branding and Transportation 672 695 1,282 1,310 Electronics 746 714 1,471 1,386 Total Transportation and Electronics Business Segment 2,143 2,191 4,247 4,241 Consumer Safety and Well-Being 280 278 546 548 Home and Auto Care 302 337 607 655 Home Improvement 369 355 699 696 Packaging and Expression 312 323 551 586 Total Consumer Business Segment 1,263 1,293 2,403 2,485 Corporate and Unallocated 86 22 112 45 Other 4 12 18 23 Total Company $ 6,255 $ 6,283 $ 12,271 $ 12,338 Three months ended Six months ended Net Sales by Geographic Area (millions) 2024 2023 2024 2023 Americas $ 3,480 $ 3,396 $ 6,630 $ 6,568 Asia Pacific 1,721 1,776 3,489 3,590 Europe, Middle East and Africa 1,054 1,111 2,152 2,180 Worldwide $ 6,255 $ 6,283 $ 12,271 $ 12,338

Divestitures

Divestitures	6 Months Ended
	Jun. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Divestitures	NOTE 4. Divestitures Refer to Note 3 to the Consolidated Financial Statements in 3M's 2023 Annual Report on Form 10-K for more information on relevant pre-2024 divestitures. On April 1, 2024, 3M completed the separation of its Health Care business (the Separation) through a pro rata distribution of 80.1% of the outstanding shares of Solventum Corporation (Solventum) to 3M stockholders. See Note 2 for additional detail, including information regarding reporting the historical net income of Solventum and applicable assets and liabilities included in the Separation in 3M's consolidated financial statements as discontinued operations.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	NOTE 5. Goodwill and Intangible Assets (Millions) Safety and Industrial Transportation and Electronics Consumer Corporate and Unallocated Total Company Balance as of December 31, 2023 $ 4,542 $ 1,512 $ 270 $ 58 $ 6,382 Translation and other (42) (10) (12) — (64) Balance as of June 30, 2024 $ 4,500 $ 1,502 $ 258 $ 58 $ 6,318 The amounts in the “Translation and other” row in the above table primarily relate to changes in foreign currency exchange rates. As of June 30, 2024, the Company's accumulated goodwill impairment loss is $0.3 billion. Acquired Intangible Assets: The carrying amount and accumulated amortization of acquired finite-lived intangible assets, in addition to the balance of non-amortizable intangible assets follow: (Millions) June 30, 2024 December 31, 2023 Customer related $ 1,328 $ 1,337 Patents 224 225 Other technology-based 373 375 Definite-lived tradenames 488 489 Other 46 48 Total gross carrying amount 2,459 2,474 Accumulated amortization — customer related (910) (883) Accumulated amortization — patents (223) (224) Accumulated amortization — other technology-based (322) (317) Accumulated amortization — definite-lived tradenames (288) (276) Accumulated amortization — other (30) (31) Total accumulated amortization (1,773) (1,731) Total finite-lived intangible assets — net 686 743 Indefinite lived intangible assets (primarily tradenames) 580 580 Total intangible assets — net $ 1,266 $ 1,323 Certain tradenames acquired by 3M are not amortized because they have been in existence for over 60 years, have a history of leading-market share positions, have been and are intended to be continuously renewed, and the associated products of which are expected to generate cash flows for 3M for an indefinite period of time. Amortization expense follows: Three months ended Six months ended (Millions) 2024 2023 2024 2023 Amortization expense $ 27 $ 29 $ 54 $ 59 Expected amortization expense for acquired amortizable intangible assets recorded as of June 30, 2024 follows: (Millions) Remainder of 2024 2025 2026 2027 2028 2029 After 2029 Amortization expense $ 52 $ 105 $ 104 $ 85 $ 59 $ 57 $ 224 3M expenses the costs incurred to renew or extend the term of intangible assets.

Restructuring Actions

Restructuring Actions	6 Months Ended
	Jun. 30, 2024
Restructuring and Related Activities [Abstract]
Restructuring Actions	NOTE 6. Restructuring Actions 2023 to 2025 Structural Reorganization Actions: As described in Note 5 in 3M's 2023 Annual Report on Form 10-K, in the first quarter of 2023, 3M announced it would undertake structural reorganization actions to reduce the size of the corporate center of the Company, simplify supply chain, streamline 3M’s geographic footprint, reduce layers of management, further align business go-to-market models to customers, and reduce manufacturing roles to align with production volumes. This aggregate initiative, beginning in the first quarter of 2023 and continuing through 2025, is expected (as updated to exclude discontinued operations) to impact approximately 8,000 positions worldwide with an expected pre-tax charge of $700 million to $800 million over that period. During 2023, management approved and committed to undertake associated actions resulting in a 2023 pre-tax charge of $415 million. During 2024, management approved and committed to undertake additional actions under this initiative impacting approximately 700 positions resulting in a pre-tax charge of $35 million and $138 million in the second quarter and six months ended June 30, 2024, respectively. Since its beginning in 2023 through committed second quarter 2024 actions, this initiative has impacted approximately 6,400 positions worldwide. Remaining activities related to the restructuring actions approved and committed through June 30, 2024 under this initiative are expected to be completed in 2025. 3M expects to commit to further actions under this initiative. The related restructuring charges for periods presented were recorded in the income (loss) statement as follows: Three months ended Six months ended (Millions) 2024 2023 2024 2023 Cost of sales $ 2 $ 44 $ 4 $ 59 Selling, general and administrative expenses 32 140 123 171 Research, development and related expenses 1 18 11 22 Total operating income impact $ 35 $ 202 $ 138 $ 252 The business segment operating income (loss) impact of these restructuring charges is summarized as follows: Three months ended June 30, 2024 2023 (Millions) Employee Related Asset-Related and Other Total Employee Related Asset-Related and Other Total Safety and Industrial $ 13 $ 5 $ 18 $ 44 $ — $ 44 Transportation and Electronics 7 4 11 25 — 25 Consumer 4 2 6 13 — 13 Corporate and unallocated — — — 100 20 120 Total operating expense $ 24 $ 11 $ 35 $ 182 $ 20 $ 202 Six months ended June 30, 2024 2023 (Millions) Employee Related Asset-Related and Other Total Employee Related Asset-Related and Other Total Safety and Industrial $ 39 $ 25 $ 64 $ 54 $ — $ 54 Transportation and Electronics 16 18 34 37 — 37 Consumer 9 11 20 16 — 16 Corporate and unallocated 6 14 20 125 20 145 Total operating expense $ 70 $ 68 $ 138 $ 232 $ 20 $ 252 Restructuring actions, including cash and non-cash impacts, follow: (Millions) Employee-Related Asset-Related and Other Total Accrued restructuring action balance as of December 31, 2023 $ 99 $ — $ 99 Incremental expense incurred in the first quarter of 2024 46 57 103 Incremental expense incurred in the second quarter of 2024 24 11 35 Non-cash changes — (68) (68) Adjustments 12 — 12 Cash payments (92) — (92) Accrued restructuring action balance as of June 30, 2024 $ 89 $ — $ 89 2023 to 2025 PFAS Exit Actions: As described in Note 5 in 3M's 2023 Annual Report on Form 10-K, 3M announced in 2022 that it will exit all PFAS manufacturing by the end of 2025. In 2023, 3M management approved and committed to undertake certain related workforce actions resulting in a pre-tax charge of $64 million primarily impacting cost of sales. During 2024, management approved and committed to undertake additional related workforce actions impacting approximately 60 positions resulting in a pre-tax charge of $8 million and $12 million primarily impacting cost of sales in the second quarter and six months ended June 30, 2024, respectively. These charges are reflected within the Transportation and Electronics business segment. This initiative, beginning in 2023 through committed second quarter 2024 actions, has impacted approximately 610 positions worldwide. The remaining period of activities related to these approved and committed actions aligns with 3M's PFAS exit timeframe. (Millions) Employee-Related Accrued restructuring action balance as of December 31, 2023 $ 60 Incremental expense incurred in the first quarter of 2024 4 Incremental expense incurred in the second quarter of 2024 8 Adjustments (4) Cash payments (17) Accrued restructuring action balance as of June 30, 2024 $ 51

Supplemental Income (Loss) Stat

Supplemental Income (Loss) Statement Information	6 Months Ended
	Jun. 30, 2024
Other Income and Expenses [Abstract]
Supplemental Income (Loss) Statement Information	NOTE 7. Supplemental Income (Loss) Statement Information Other expense (income), net consists of the following: Three months ended Six months ended (Millions) 2024 2023 2024 2023 Interest expense $ 322 $ 144 $ 663 $ 267 Interest income (143) (47) (253) (88) Pension and postretirement net periodic benefit cost (benefit) 796 (25) 785 (51) Solventum ownership - change in value (1,113) — (1,113) — Total $ (138) $ 72 $ 82 $ 128 Beginning in the second quarter and third quarter of 2023, interest expense also includes imputed interest associated with the obligations resulting from the PWS Settlement and the CAE Settlement, respectively (discussed in Note 17). Pension and postretirement net periodic benefit income described in the table above include all components of defined benefit plan net periodic benefit cost (benefit) except service cost, which is reported in various operating expense lines. The second quarter of 2024 non-service cost component above was impacted by a $795 million pension settlement charge. Refer to Note 13 for additional details on the components of pension and postretirement net periodic benefit cost (benefit).

Supplemental Equity and Compreh

Supplemental Equity and Comprehensive Income (Loss) Information	6 Months Ended
	Jun. 30, 2024
Stockholders' Equity Note [Abstract]
Supplemental Equity and Comprehensive Income (Loss) Information	NOTE 8. Supplemental Equity and Comprehensive Income (Loss) Information Cash dividends declared and paid totaled $1.51 and $0.70 for the first and second quarters of 2024, respectively, and $1.50 per share for each of the first and second quarters of 2023, or $2.21 and $3.00 per share for the first six months of 2024 and 2023, respectively. The table below presents the consolidated changes in equity for three and six months ended June 30, 2024 and 2023: 3M Company Shareholders (Millions) Total Common Stock and Additional Paid-in Capital Retained Earnings Treasury Stock Accumulated Other Comprehensive Income (Loss) Non-controlling Interest Balance at March 31, 2024 $ 4,933 $ 6,982 $ 37,472 $ (32,762) $ (6,826) $ 67 Net income (loss) 1,151 1,145 6 Other comprehensive income (loss), net of tax 674 675 (1) Solventum spin-off (2,169) (2,753) 584 Dividends declared (386) (386) Stock-based compensation 173 173 Reacquired stock (400) (400) Issuances pursuant to stock option and benefit plans 12 (3) 15 Balance at June 30, 2024 $ 3,988 $ 7,155 $ 35,475 $ (33,147) $ (5,567) $ 72 Balance at March 31, 2023 $ 15,351 $ 6,825 $ 47,966 $ (32,963) $ (6,530) $ 53 Net income (6,836) (6,841) 5 Other comprehensive income (loss), net of tax 98 97 1 Dividends declared (828) (828) Stock-based compensation 42 42 Issuances pursuant to stock option and benefit plans 30 (7) 37 Balance at June 30, 2023 $ 7,857 $ 6,867 $ 40,290 $ (32,926) $ (6,433) $ 59 3M Company Shareholders (Millions) Total Common Stock and Additional Paid-in Capital Retained Earnings Treasury Stock Accumulated Other Comprehensive Income (Loss) Non-controlling Interest Balance at December 31, 2023 $ 4,868 $ 6,965 $ 37,479 $ (32,859) $ (6,778) $ 61 Net income (loss) 2,084 2,073 11 Total other comprehensive income (loss), net of tax 627 627 — Solventum spin-off (2,169) (2,753) 584 Dividends declared (1,221) (1,221) Stock-based compensation 190 190 Reacquired stock (421) (421) Issuances pursuant to stock option and benefit plans 30 (103) 133 Balance at June 30, 2024 $ 3,988 $ 7,155 $ 35,475 $ (33,147) $ (5,567) $ 72 Balance at December 31, 2022 $ 14,770 $ 6,700 $ 47,950 $ (33,255) $ (6,673) $ 48 Net income (5,855) (5,865) 10 Total other comprehensive income (loss), net of tax 241 240 1 Dividends declared (1,655) (1,655) Stock-based compensation 167 167 Reacquired stock (29) (29) Issuances pursuant to stock option and benefit plans 218 (140) 358 Balance at June 30, 2023 $ 7,857 $ 6,867 $ 40,290 $ (32,926) $ (6,433) $ 59 The table below presents the changes in accumulated other comprehensive income (loss) attributable to 3M (AOCI), including the reclassifications out of AOCI by component for three and six months ended June 30, 2024 and 2023: (Millions) Cumulative Translation Adjustment Defined Benefit Pension and Postretirement Plans Adjustment Cash Flow Hedging Instruments, Unrealized Gain (Loss) Total Accumulated Other Comprehensive Income (Loss) Balance at March 31, 2024, net of tax: $ (2,715) $ (4,083) $ (28) $ (6,826) Other comprehensive income (loss), before tax: Amounts before reclassifications (148) 218 23 93 Amounts reclassified out 11 876 (30) 857 Total other comprehensive income (loss), before tax (137) 1,094 (7) 950 Tax effect 2 (7) (268) — (275) Total other comprehensive income (loss), net of tax (144) 826 (7) 675 Solventum spin-off 64 520 — 584 Balance at June 30, 2024, net of tax: $ (2,795) $ (2,737) $ (35) $ (5,567) Balance at March 31, 2023, net of tax: $ (2,712) $ (3,787) $ (31) $ (6,530) Other comprehensive income (loss), before tax: Amounts before reclassifications 3 — 72 75 Amounts reclassified out 39 65 (40) 64 Total other comprehensive income (loss), before tax 42 65 32 139 Tax effect 2 (18) (15) (9) (42) Total other comprehensive income (loss), net of tax 24 50 23 97 Balance at June 30, 2023, net of tax: $ (2,688) $ (3,737) $ (8) $ (6,433) (Millions) Cumulative Translation Adjustment Defined Benefit Pension and Postretirement Plans Adjustment Cash Flow Hedging Instruments, Unrealized Gain (Loss) Total Accumulated Other Comprehensive Income (Loss) Balance at December 31, 2023, net of tax: $ (2,506) $ (4,218) $ (54) $ (6,778) Other comprehensive income (loss), before tax: Amounts before reclassifications (401) 285 84 (32) Amounts reclassified out 68 972 (57) 983 Total other comprehensive income (loss), before tax (333) 1,257 27 951 Tax effect 2 (20) (296) (8) (324) Total other comprehensive income (loss), net of tax (353) 961 19 627 Solventum spin-off 64 520 — 584 Balance at June 30, 2024, net of tax: $ (2,795) $ (2,737) $ (35) $ (5,567) Balance at December 31, 2022, net of tax: $ (2,828) $ (3,838) $ (7) $ (6,673) Other comprehensive income (loss), before tax: Amounts before reclassifications 108 — 78 186 Amounts reclassified out 39 129 (81) 87 Total other comprehensive income (loss), before tax 147 129 (3) 273 Tax effect 2 (7) (28) 2 (33) Total other comprehensive income (loss), net of tax 140 101 (1) 240 Balance at June 30, 2023, net of tax: $ (2,688) $ (3,737) $ (8) $ (6,433) Includes tax expense (benefit) reclassified out of AOCI related to the following: Three months ended June 30, Six months ended June 30, (millions) 2024 2023 2024 2023 Cumulative Translation Adjustment $ — $ — $ — $ — Defined benefit pension and postretirement plans adjustment (216) (15) (229) (28) Cash flow hedging instruments, unrealized gain/loss 7 8 13 18 Income taxes are not provided for foreign translation relating to permanent investments in international subsidiaries, but tax effects within cumulative translation do include impacts from items such as net investment hedge transactions. The Company uses the portfolio approach for releasing income tax effects from accumulated other comprehensive income. Additional details on the amounts reclassified from accumulated other comprehensive income (loss) into consolidated income (loss) include: • Cumulative translation adjustment: amounts were reclassified into selling, general and administrative expense. In 2024, this was associated with country exits as part of streamlining 3M’s geographic footprint (see Note 6). • Defined benefit pension and postretirement plan adjustments: amounts were reclassified into other (expense) income, net (see Note 13). • Cash flow hedging instruments, unrealized gain (loss): foreign currency forward/option contacts amounts were reclassified into cost of sales; interest rate contract amounts were reclassified into interest expense (see Note 15). • The tax effects, if applicable, associated with these reclassifications were reflected in provision for income taxes.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 9. Income Taxes The effective tax rate on a continuing operations basis for the second quarter of 2024 was 14.4 percent on pre-tax income compared to 24.0 percent on a pre-tax loss in the prior year. The effective tax rate for the first six months of 2024 was 18.1 percent compared to 24.6 percent in the prior year. The primary factors that impacted the comparison of these rates year-over -year were the second quarter 2023 charge related to the settlement agreement with public water systems in the United States regarding PFAS (see Note 17) and the tax rate associated with second quarter 2024 benefit related to the change in value of the retained ownership interest in Solventum. The total amounts of unrecognized tax benefits that, if recognized, would affect the effective tax rate as of June 30, 2024 and December 31, 2023 on a continuing operations basis are $691 million and $671 million, respectively. It is reasonably possible that the amount of unrecognized tax benefits could significantly change within the next 12 months. At this time, the Company is not able to estimate the range by which these potential events could impact 3M’s unrecognized tax benefits in the next 12 months. The net deferred tax assets are included as components of Other Assets and Other Liabilities within the Consolidated Balance Sheet. As of June 30, 2024, 3M's net non current deferred tax asset balance was approximately $4.0 billion. This included a balance of approximately $3.2 billion as a result of the 2023 pre-tax charges related to the PWS Settlement and the CAE Settlement (both discussed in Note 17). As of June 30, 2024 and December 31, 2023, on a continuing operations basis, the Company had valuation allowances of $1,474 million and $689 million on its deferred tax assets, respectively. The primary factor that increased the valuation allowance balance as of June 30, 2024 is a valuation allowance related to the difference in basis of the retained ownership interest in Solventum. In connection with the completion of the separation of Solventum in April 2024, 3M re-evaluated its global cash needs and certain unrepatriated earnings are no longer considered permanently reinvested, which resulted in a charge of approximately $100 million in the second quarter of 2024. The Company has not provided deferred taxes on approximately $1.0 billion of undistributed earnings from non-U.S. subsidiaries as of June 30, 2024 which are indefinitely reinvested in operations. Because of the multiple avenues by which to repatriate the earnings to minimize tax cost, and because a large portion of these earnings are not liquid, it is not practical to determine the income tax liability that would be payable if such earnings were not reinvested indefinitely. In 2021, the Organization for Economic Cooperation and Development (OECD) published Pillar Two Model Rules defining a global minimum tax, which calls for the taxation of large corporations at a minimum rate of 15%. The OECD has since issued administrative guidance providing transition and safe harbor rules around the implementation of the Pillar Two global minimum tax. Effective January 1, 2024, a number of countries have proposed or enacted legislation to implement core elements of the Pillar Two proposal. Pillar Two did not have a significant impact on 3M's second quarter 2024 results. While 3M is monitoring developments and evaluating the potential impact on future periods, 3M does not expect Pillar Two to have a significant impact on its 2024 financial results.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	NOTE 10. Earnings (Loss) Per Share The difference in the weighted average 3M shares outstanding for calculating basic and diluted earnings per share attributable to 3M common shareholders is the result of the dilution associated with the Company’s stock-based compensation plans. Certain awards outstanding under these stock-based compensation plans were not included in the computation of diluted earnings per share attributable to 3M common shareholders because they would have had an anti-dilutive effect of 33.1 million and 32.9 million average options for the three and six months ended June 30, 2024, respectively, and 36.9 million and 36.5 million average options for the three and six months ended June 30, 2023, respectively. In periods of net losses, these anti-dilutive effects include all weighted option shares outstanding and weighted average shares is the same for the calculations of both basic and diluted loss per share. The computations for basic and diluted earnings (loss) per share follow: Three months ended Six months ended (Amounts in millions, except per share amounts) 2024 2023 2024 2023 Numerator: Net income (loss) from continuing operations attributable to 3M $ 1,204 $ (7,171) $ 1,909 $ (6,509) Net income (loss) from discontinued operations, net of taxes (59) 330 164 644 Net income (loss) attributable to 3M $ 1,145 $ (6,841) $ 2,073 $ (5,865) Denominator: Denominator for weighted average 3M common shares outstanding – basic 553.8 553.9 554.4 553.3 Dilution associated with stock-based compensation plans 1.0 — 0.9 — Denominator for weighted average 3M common shares outstanding – diluted 554.8 553.9 555.3 553.3 Earnings (loss) per share attributable to 3M common shareholders: Earnings (loss) per share from continuing operations — basic $ 2.17 $ (12.94) $ 3.44 $ (11.76) Earnings (loss) per share from discontinued operations — basic (0.10) 0.59 0.30 1.16 Earnings (loss) per share — basic $ 2.07 $ (12.35) $ 3.74 $ (10.60) Earnings (loss) per share from continuing operations — diluted $ 2.17 $ (12.94) $ 3.44 $ (11.76) Earnings (loss) per share from discontinued operations — diluted (0.10) 0.59 0.29 1.16 Earnings (loss) per share — diluted $ 2.07 $ (12.35) $ 3.73 $ (10.60)

Marketable Securities

Marketable Securities	6 Months Ended
	Jun. 30, 2024
Debt Securities, Available-for-Sale [Abstract]
Marketable Securities	NOTE 11. Marketable Securities The Company invests in certificates of deposit/time deposits, commercial paper, and other securities. The following is a summary of amounts recorded on the Consolidated Balance Sheet for marketable securities (current and non-current). (Millions) June 30, 2024 December 31, 2023 Asset backed securities $ 4 $ — Foreign corporate debt 6 — U.S. government securities 27 — Corporate debt securities 70 — Commercial paper 40 — Certificates of deposit/time deposits 91 46 U.S. treasury securities 13 — U.S. municipal securities 4 4 Current marketable securities 255 50 Asset backed securities 4 — Corporate debt securities 10 — U.S. municipal securities 20 20 Non-current marketable securities 34 20 Total marketable securities $ 289 $ 70 At June 30, 2024 and December 31, 2023, gross unrealized, gross realized, and net realized gains and/or losses (pre-tax) were not material. The balances at June 30, 2024 for marketable securities by contractual maturity are shown below. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (Millions) Due in one year or less $ 255 Due after one year through five years 25 Due after five years through ten years 9 Total marketable securities $ 289

Long-Term Debt and Short-Term B

Long-Term Debt and Short-Term Borrowings	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Long-Term Debt and Short-Term Borrowings	NOTE 12. Long-Term Debt and Short-Term Borrowings 2023 issuances, maturities, and extinguishments of short- and long-term debt are described in Note 13 to the Consolidated Financial Statements in 3M's 2023 Annual Report on Form 10-K. The Consolidated Statements of Cash Flows include the results of continuing and discontinued operations and, therefore, information regarding similar debt-related activity for 2024 includes that associated with Solventum through its April 2024 Separation. The Company had no commercial paper outstanding at June 30, 2024, compared to $1.8 billion commercial paper outstanding as of December 31, 2023. In the first quarter of 2024, Solventum, prior to the Separation discussed in Note 2, issued a total of $8.4 billion in aggregate principal amount of senior unsecured debt and term loans. Also during the first quarter of 2024, Solventum further entered into a revolving credit facility of $2 billion which was undrawn as of March 31, 2024. These Solventum items were guaranteed by 3M until the completion of the Separation on April 1, 2024 and obligations under these notes, loans and facilities became, as transferred obligations, the sole responsibility of Solventum after the Separation. In February 2024, 3M repaid $1.1 billion aggregate principal amount of medium-term notes that matured. Future Maturities of Long-term Debt: Maturities of long-term debt in the table below reflect the impact of put provisions associated with certain debt instruments and are net of the unamortized debt issue costs such that total maturities equal the carrying value of long-term debt as of June 30, 2024. The maturities of long-term debt for the periods subsequent to June 30, 2024 are as follows (in millions): Remainder of 2024 2025 2026 2027 2028 2029 After 2029 Total $ 53 $ 1,868 $ 1,540 $ 847 $ 818 $ 1,790 $ 6,167 $ 13,083

Pension and Postretirement Bene

Pension and Postretirement Benefit Plans	6 Months Ended
	Jun. 30, 2024
Retirement Benefits [Abstract]
Pension and Postretirement Benefit Plans	NOTE 13. Pension and Postretirement Benefit Plans The service cost component of defined benefit net periodic benefit cost is recorded in cost of sales; selling, general and administrative expenses; and research, development and related expenses. The other components of net periodic benefit cost are reflected in other expense (income), net. Effective April 1, 2024, approximately $2.7 billion of benefit obligations and $2.4 billion of plan assets for certain pension and postretirement benefit plans, were transferred to Solventum, which is treated as a discontinued operation. Components of net periodic benefit cost and other supplemental information for the three and six months ended June 30, 2024 and 2023 follow: Three months ended June 30, Qualified and Non-qualified Pension Benefits Postretirement Benefits United States International (Millions) 2024 2023 2024 2023 2024 2023 Net periodic benefit cost (benefit) Operating expense Service cost $ 29 $ 43 $ 14 $ 20 $ 5 $ 6 Non-operating expense Interest cost 141 165 49 54 21 23 Expected return on plan assets (196) (244) (80) (75) (15) (19) Amortization of transition asset — — 1 1 — — Amortization of prior service benefit (4) (6) — — (6) (8) Amortization of net actuarial loss 83 74 3 2 4 2 Settlements, curtailments, special termination benefits and other 795 — — — — — Total non-operating expense (benefit) 819 (11) (27) (18) 4 (2) Total net periodic benefit cost (benefit) 848 32 (13) 2 9 4 Service cost - continuing operations $ 29 $ 35 $ 14 $ 16 $ 5 $ 5 Service cost - discontinued operations — 8 — 4 — 1 Total service cost 29 43 14 20 5 6 Non-operating expense (benefit) - continuing operations 819 (7) (27) (16) 4 (2) Non-operating expense (benefit) - discontinued operations — (4) — (2) — — Total non-operating expense (benefit) 819 (11) (27) (18) 4 (2) Total net periodic benefit cost (benefit) - continuing operations 848 28 (13) — 9 3 Total net periodic benefit cost (benefit) - discontinued operations — 4 — 2 — 1 Total net periodic benefit cost (benefit) $ 848 $ 32 $ (13) $ 2 $ 9 $ 4 Six months ended June 30, Qualified and Non-qualified Pension Benefits Postretirement Benefits United States International (Millions) 2024 2023 2024 2023 2024 2023 Net periodic benefit cost (benefit) Operating expense Service cost $ 66 $ 86 $ 35 $ 39 $ 12 $ 12 Non-operating expense Interest cost 301 331 103 109 43 45 Expected return on plan assets (433) (488) (167) (150) (34) (38) Amortization of transition asset — — 2 1 — — Amortization of prior service benefit (8) (12) 1 1 (12) (16) Amortization of net actuarial loss 178 147 6 4 10 4 Settlements, curtailments, special termination benefits and other 795 — — — — — Total non-operating expense (benefit) 833 (22) (55) (35) 7 (5) Total net periodic benefit cost (benefit) 899 64 (20) 4 19 7 Service cost - continuing operations $ 59 $ 70 $ 30 $ 31 $ 11 $ 10 Service cost - discontinued operations 7 16 5 8 1 2 Total service cost 66 86 35 39 12 12 Non-operating expense (benefit) - continuing operations 833 (14) (55) (33) 7 (4) Non-operating expense (benefit) - discontinued operations — (8) — (2) — (1) Total non-operating expense (benefit) 833 (22) (55) (35) 7 (5) Total net periodic benefit cost (benefit) - continuing operations 892 56 (25) (2) 18 6 Total net periodic benefit cost (benefit) - discontinued operations 7 8 5 6 1 1 Total net periodic benefit cost (benefit) $ 899 $ 64 $ (20) $ 4 $ 19 $ 7 For the six months ended June 30, 2024 contributions totaling $81 million were made to the Company’s U.S. and international pension plans and $5 million to its postretirement plans, including discontinued operations. Future contributions will depend on market conditions, interest rates and other factors. 3M does not expect the previously disclosed range of $100 million to $200 million of expected 2024 cash contributions to its U.S. and international retirement plans to be materially impacted by the April 1, 2024 separation of Solventum (see Note 2). 3M’s annual measurement date for pension and postretirement assets and liabilities is December 31 each year, which is also the date used for the related annual measurement assumptions. In the second quarter of 2024, 3M recorded a non-cash pension settlement charge of approximately $795 million reflected in other expense (income), net as a result of transferring approximately $2.5 billion of its U.S. pension payment obligations and related plan assets to an insurance company. The pension risk transfer required remeasurement of the plan prior to the calculation of the settlement charge. The net impact of the pension risk transfer and the remeasurement was a decrease of approximately $220 million in the non-current liability for pensions (and corresponding decrease in accumulated comprehensive loss, before deferred taxes). Assumptions used for this remeasurement included discount rates determined using June 30, 2024 market conditions and calculated using the same methodology as disclosed in Note 14 to the Consolidated Financial Statements in 3M's 2023 Annual Report on Form 10-K. Using this methodology, the Company determined a discount rate of 5.43% for the U.S. pension plan as of June 30, 2024. The Company also reduced the expected return on assets assumption determined using June 30, 2024 market conditions and calculated using the same methodology as used at the annual measurement as of December 31, 2023. All other assumptions were consistent with the December 31, 2023 disclosures. This remeasurement will impact net periodic benefit cost for the remainder of 2024. As of March 31, 2024, 3M transferred eligible U.S. Solventum employees and retirees to new U.S. defined benefit pension and postretirement plans with the same benefits of their current plans. The transfer required remeasurement of the plans prior to the calculation of this split. The net impact of the remeasurement was a decrease of approximately $70 million in the non-current liability for pension and postretirement benefits (and corresponding decrease in accumulated comprehensive loss, before deferred taxes). Assumptions used for this remeasurement included discount rates determined using March 31, 2024 market conditions and calculated using the same methodology as disclosed in Note 14 to the Consolidated Financial Statements in 3M's 2023 Annual Report on Form 10-K. All other assumptions were consistent with the December 31, 2023 disclosures. Using this methodology, the Company determined a discount rate of 5.22% for the U.S. pension plans and 5.19% for the U.S. postretirement benefit plans as of March 31, 2024, which are increases of 0.24 percentage points and 0.25 percentage points, respectively, from the rates used as of December 31, 2023. This remeasurement did not impact consolidated income for the three months ended March 31, 2024, but will impact net periodic benefit cost for the remainder of 2024. As of March 31, 2024, there were several small international pension plans remeasured for purposes of transferring Solventum employees to new pension plans, the impact of which was not material.

Supplier Finance Program Obliga

Supplier Finance Program Obligations	6 Months Ended
	Jun. 30, 2024
Payables and Accruals [Abstract]
Supplier Finance Program Obligations	NOTE 14. Supplier Finance Program Obligations Under supplier finance programs, 3M agrees to pay participating banks the stated amount of confirmed invoices from its designated suppliers on the original maturity dates of the invoices, generally within 90 days of the invoice date. 3M or the banks may terminate the agreements with advance notice. Separately, the banks may have arrangements with the suppliers that provide them the option to request early payment from the banks for invoices confirmed by 3M. 3M's outstanding balances of confirmed invoices in the programs as of June 30, 2024 and December 31, 2023 were approximately $320 million and $270 million, respectively. These amounts are included within accounts payable

Derivatives

Derivatives	6 Months Ended
	Jun. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	NOTE 15. Derivatives The Company uses interest rate swaps and forward and option contracts to manage risks generally associated with foreign exchange rate and interest rate fluctuations. Note 16 to the Consolidated Financial Statements in 3M's 2023 Annual Report on Form 10-K explains the types of derivatives and financial instruments used by 3M, how and why 3M uses such instruments, and how such instruments are accounted for. It also contains information regarding previously initiated contracts or instruments. Additional information with respect to derivatives is included elsewhere as follows: • Impact on other comprehensive income of nonderivative hedging and derivative instruments is included in Note 7. • Fair value of derivative instruments is included in Note 16. • Derivatives and/or hedging instruments associated with the Company’s long-term debt are described in Note 13 to the Consolidated Financial Statements in 3M's 2023 Annual Report on Form 10-K. Refer to the section below titled Statement of Income (Loss) Location and Impact of Cash Flow and Fair Value Derivative Instruments and Derivatives Not Designated as Hedging Instruments for details on the location within the consolidated statements of income (loss) for amounts of gains and losses related to derivative instruments designated as cash flow or fair value hedges (along with similar information relative to the hedged items) and derivatives not designated as hedging instruments. Additional information relative to cash flow hedges, fair value hedges, net investment hedges and derivatives not designated as hedging instruments is included below as applicable. Cash Flow Hedges: As of June 30, 2024, the Company had a balance of $35 million associated with the after-tax net unrealized loss associated with cash flow hedging instruments recorded in accumulated other comprehensive income (loss). This includes a remaining balance of $83 million (after-tax loss) related to forward starting interest rate swap and treasury rate lock contracts terminated in 2019 concurrent with associated debt issuances, which is being amortized over the respective lives of the underlying notes. Based on exchange rates as of June 30, 2024 of the total after-tax net unrealized balance as of June 30, 2024, 3M expects to reclassify approximately $38 million after-tax net unrealized gain over the next 12 months (with the impact offset by earnings/losses from underlying hedged items). The amount of pretax gain (loss) recognized in other comprehensive income (loss) related to derivative instruments designated as cash flow hedges is provided in the following table. Pretax Gain (Loss) Recognized in Other Comprehensive Income (Loss) on Derivative Three months ended Six months ended (Millions) 2024 2023 2024 2023 Foreign currency forward/option contracts $ 23 $ 72 $ 84 $ 78 Fair Value Hedges: The following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustments for active fair value hedges, as well as remaining amounts for discontinued fair value hedges: Location on the Consolidated Balance Sheet (Millions) Carrying Value of the Hedged Liabilities Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Value of the Hedged Liabilities June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 Long-term debt $ 909 $ 918 $ (93) $ (84) Net Investment Hedges: At June 30, 2024, the total notional amount of foreign exchange forward contracts designated in net investment hedges was approximately 150 million euros, along with a principal amount of long-term debt instruments designated in net investment hedges totaling 1.8 billion euros. The maturity dates of these derivative and nonderivative instruments designated in net investment hedges range from 2024 to 2031. The amount of gain (loss) excluded from effectiveness testing recognized in income relative to instruments designated in net investment hedge relationships is not material. The amount of pre-tax gain (loss) recognized in other comprehensive income (loss) related to derivative and nonderivative instruments designated as net investment hedges are as follows. Pretax Gain (Loss) Recognized as Cumulative Translation within Other Comprehensive Income (Loss) Three months ended Six months ended (Millions) 2024 2023 2024 2023 Foreign currency denominated debt $ 13 $ (22) $ 56 $ (65) Foreign currency forward contracts 2 (1) 5 (3) Total $ 15 $ (23) $ 61 $ (68) Derivatives Not Designated as Hedging Instruments: Derivatives not designated as hedging instruments include de-designated foreign currency forward and option contracts that formerly were designated in cash flow hedging relationships (as referenced in the Cash Flow Hedges section above). In addition, 3M enters into foreign currency contracts that are not designated in hedging relationships to offset, in part, the impacts of changes in value of various non-functional currency denominated items including certain intercompany financing balances. These derivative instruments are not designated in hedging relationships; therefore, fair value gains and losses on these contracts are recorded in earnings. The Company does not hold or issue derivative financial instruments for trading purposes. Statement of Income (Loss) Location and Impact of Cash Flow and Fair Value Derivative Instruments and Derivatives Not Designated as Hedging Instruments: Three months ended June 30, Six months ended June 30, Cost of sales Other expense (income), net Cost of sales Other expense (income), net (Millions) 2024 2023 2024 2023 2024 2023 2024 2023 Total consolidated financial statement line item amount $ 3,571 $ 3,728 $ (138) $ 72 $ 7,056 $ 7,472 $ 82 $ 128 Pre-tax amounts recognized in income related to derivative instruments Information regarding cash flow and fair value hedging relationships: (Gain) or loss on cash flow hedging relationships: Foreign currency forward/option contracts: Amount of (gain) or loss reclassified from accumulated other comprehensive income (loss) into income * (32) (42) — — (61) (85) — — Interest rate contracts: Amount of (gain) or loss reclassified from accumulated other comprehensive income (loss) into income — — 2 2 — — 4 4 (Gain) or loss on fair value hedging relationships: Interest rate contracts: Hedged items — — 2 (9) — — (9) 3 Derivatives designated as hedging instruments — — (2) 9 — — 9 (3) Information regarding derivatives not designated as hedging instruments: (Gain) or loss on derivatives not designated as instruments: Foreign currency forward/option contracts 2 13 4 (39) 7 5 6 (13) * For periods prior to the April 1, 2024 separation of Solventum, these include certain insignificant amounts attributable to discontinued operations. Location, Fair Value, and Gross Notional Amounts of Derivative Instruments: The following tables summarize the fair value of 3M’s derivative instruments, excluding nonderivative instruments used as hedging instruments, and their location in the consolidated balance sheet. Notional amounts below are presented at period end foreign exchange rates, except for certain interest rate swaps, which are presented using the inception date’s foreign exchange rate. Gross Notional Amount Assets Liabilities (Millions) Location Fair Value Amount Location Fair Value Amount June 30, December 31, June 30, December 31, June 30, December 31, Derivatives designated as hedging instruments Foreign currency forward/option contracts $ 1,821 $ 2,109 Other current assets $ 74 $ 68 Other current liabilities $ 5 $ 27 Foreign currency forward/option contracts 725 342 Other assets 12 11 Other liabilities 5 5 Interest rate contracts 800 800 Other assets — — Other liabilities 96 88 Total derivatives designated as hedging instruments 86 79 106 120 Derivatives not designated as hedging instruments Foreign currency forward/option contracts 659 1,023 Other current assets — 5 Other current liabilities 1 7 Total derivatives not designated as hedging instruments — 5 1 7 Total derivative instruments $ 86 $ 84 $ 107 $ 127 Credit Risk and Offsetting of Assets and Liabilities of Derivative Instruments: The Company is exposed to credit loss in the event of nonperformance by counterparties in interest rate swaps, currency swaps, and forward and option contracts. However, the Company’s risk is limited to the fair value of the instruments. The Company actively monitors its exposure to credit risk through the use of credit approvals and credit limits, and by selecting major international banks and financial institutions as counterparties. 3M enters into master netting arrangements with counterparties when possible to mitigate credit risk in derivative transactions. A master netting arrangement may allow each counterparty to net settle amounts owed between a 3M entity and the counterparty as a result of multiple, separate derivative transactions. The Company does not anticipate nonperformance by any of these counterparties. 3M has elected to present the fair value of derivative assets and liabilities within the Company’s consolidated balance sheet on a gross basis even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. 3M determined that the impact of the amount of eligible offsetting derivative assets and liabilities was not material if it had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria in the event of default or termination as stipulated by the terms of netting arrangements with each of the counterparties. For each counterparty, if netted, the Company would offset the asset and liability balances of all derivatives at the end of the reporting period based on the 3M entity that is a party to the transactions. Derivatives not subject to master netting agreements are not eligible for net presentation. For the periods presented, 3M has not received cash collateral from derivative counterparties. Currency Effects: 3M estimates that year-on-year foreign currency transaction effects, including hedging impacts, increased pre-tax income from continuing operations by approximately $2 million and decreased pre-tax income from continuing operations by approximately $19 million for the three and six months ended June 30, 2024, respectively, and decreased pre-tax loss from continuing operations by approximately $32 million and $62 million for the three and six months ended June 30, 2023, respectively. These estimates include transaction gains and losses, including derivative instruments designed to reduce foreign currency exchange rate risks.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	NOTE 16. Fair Value Measurements 3M follows ASC 820, Fair Value Measurements and Disclosures, with respect to assets and liabilities that are measured at fair value on a recurring basis and nonrecurring basis. Refer to Note 17 to the Consolidated Financial Statements in 3M's 2023 Annual Report on Form 10-K for a qualitative discussion of the assets and liabilities that are measured at fair value on a recurring and nonrecurring basis, a description of the valuation methodologies used by 3M, and categorization within the valuation framework of ASC 820. The following table provide information by level for material assets and liabilities that are measured at fair value on a recurring basis at June 30, 2024 and December 31, 2023. Fair Value at Fair Value Measurements Using Inputs Considered as Level 1 Level 2 Level 3 Description (Millions) June 30, December 31, June 30, December 31, June 30, December 31, June 30, December 31, Assets: Available-for-sale: Marketable securities: Asset backed securities $ 8 $ — $ — $ — $ 8 $ — $ — $ — Foreign corporate debt 6 — — — 6 — — — U.S. government securities 27 — 27 — — — — — Corporate debt securities 80 — — — 80 — — — Commercial paper 40 — — — 40 — — — Certificates of deposit/time deposits 91 46 — — 91 46 — — U.S. treasury securities 13 — 13 — — — — — U.S. municipal securities 24 24 — — — — 24 24 Solventum common stock 1,817 — 1,817 — — — — — Derivative instruments — assets: Foreign currency forward/option contracts 86 84 — — 86 84 — — Liabilities: Derivative instruments — liabilities: Foreign currency forward/option contracts 11 39 — — 11 39 — — Interest rate contracts 96 88 — — 96 88 — — The Company had no material activity with level 3 assets and liabilities during the periods presented. Solventum Corporation common stock is carried at stock prices that are readily available from active markets and are representative of fair value. 3M classifies this investment as Level 1. It is included within other assets on the Company’s consolidated balance sheet. In addition, the plan assets of 3M’s pension and postretirement benefit plans are measured at fair value on a recurring basis (at least annually). Refer to Note 14 to the Consolidated Financial Statements in 3M's 2023 Annual Report on Form 10-K. Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis: 3M had no material measurements at fair value on a nonrecurring basis of applicable assets or liabilities for the second quarter and first six months of 2024 and 2023. Fair Value of Financial Instruments : The Company’s financial instruments include cash and cash equivalents, marketable securities, accounts receivable, certain investments, accounts payable, borrowings, and derivative contracts. The fair values of cash equivalents, accounts receivable, accounts payable, and short-term borrowings and current portion of long-term debt approximated carrying values because of the short-term nature of these instruments. Available-for-sale marketable securities, in addition to certain investments and derivative instruments, are recorded at fair values as indicated in the preceding disclosures. To estimate fair values (classified as level 2) for its long-term debt, the Company utilized third-party quotes, which are derived all or in part from model prices, external sources, market prices, or the third-party’s internal records. Information with respect to the carrying amounts and estimated fair values of these financial instruments follow: June 30, 2024 December 31, 2023 (Millions) Carrying Value Fair Value Carrying Value Fair Value Long-term debt, excluding current portion $ 11,781 $ 10,374 $ 13,088 $ 11,859

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 17. Commitments and Contingencies Legal Proceedings: The Company and some of its subsidiaries are involved in numerous claims and lawsuits, principally in the United States, and regulatory proceedings worldwide. These claims, lawsuits and proceedings relate to matters including, but not limited to, products liability (involving products that the Company now or formerly manufactured and sold), intellectual property, commercial, antitrust, federal healthcare program related laws and regulations, such as the False Claims Act and anti-kickback laws, securities, and environmental laws in the United States and other jurisdictions. Unless otherwise stated, the Company is vigorously defending all such litigation and proceedings. From time to time, the Company also receives subpoenas, investigative demands or requests for information from various government agencies in the United States and foreign countries. The Company generally responds in a cooperative, thorough and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. Such requests can also lead to the assertion of claims or the commencement of administrative, civil, or criminal legal proceedings against the Company and others, as well as to settlements. The outcomes of legal proceedings and regulatory matters are often difficult to predict. Any determination that the Company’s operations or activities are not, or were not, in compliance with applicable laws or regulations could result in the imposition of fines, civil or criminal penalties, and equitable remedies, including disgorgement, suspension or debarment or injunctive relief. Process for Disclosure and Recording of Liabilities Related to Legal Proceedings: Many lawsuits and claims involve highly complex issues relating to causation, scientific evidence, and alleged actual damages, all of which are otherwise subject to substantial uncertainties. Assessments of lawsuits and claims can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. The categories of legal proceedings in which the Company is involved may include multiple lawsuits and claims, may be spread across multiple jurisdictions and courts which may handle the lawsuits and claims differently, may involve numerous and different types of plaintiffs, raising claims and legal theories based on specific allegations that may not apply to other matters, and may seek substantial compensatory and, in some cases, punitive, damages. These and other factors contribute to the complexity of these lawsuits and claims and make it difficult for the Company to predict outcomes and make reasonable estimates of any resulting losses. The Company's ability to predict outcomes and make reasonable estimates of potential losses is further influenced by the fact that a resolution of one or more matters within a category of legal proceedings may impact the resolution of other matters in that category in terms of timing, amount of liability, or both. When making determinations about recording liabilities related to legal proceedings, the Company complies with the requirements of ASC 450, Contingencies, and related guidance, and records liabilities in those instances where it can reasonably estimate the amount of the loss and when the loss is probable. Where the reasonable estimate of the probable loss is a range, the Company records as an accrual in its financial statements the most likely estimate of the loss, or the low end of the range if there is no one best estimate. The Company either discloses the amount of a possible loss or range of loss in excess of established accruals if estimable, or states that such an estimate cannot be made. The Company discloses significant legal proceedings even where liability is not probable or the amount of the liability is not estimable, or both, if the Company believes there is at least a reasonable possibility that a loss may be incurred. Based on experience and developments, the Company reexamines its estimates of probable liabilities and associated expenses and receivables each period, and whether a loss previously determined to not be reasonably estimable and/or not probable is now able to be reasonably estimated or has become probable. Where appropriate, the Company makes additions to or adjustments of its reasonably estimated losses and/or accruals. As a result, the current accruals and/or estimates of loss and the estimates of the potential impact on the Company’s consolidated financial position, results of operations and cash flows for the legal proceedings and claims pending against the Company will likely change over time. Because litigation is subject to inherent uncertainties, and unfavorable rulings or developments could occur, the Company may ultimately incur charges substantially in excess of presently recorded liabilities, including with respect to matters for which no accruals are currently recorded because losses are not currently probable and reasonably estimable. Many of the matters described herein are at varying stages, seek an indeterminate amount of damages or seek damages in amounts that the Company believes are not indicative of the ultimate losses that may be incurred. It is not uncommon for claims to be resolved over many years. As a matter progresses, the Company may receive information, through plaintiff demands, through discovery, in the form of reports of purported experts, or in the context of settlement or mediation discussions that purport to quantify an amount of alleged damages, but with which the Company may not agree. Such information may or may not lead the Company to determine that it is able to make a reasonable estimate as to a probable loss or range of loss in connection with a matter. However, even when a loss or range of loss is not probable and reasonably estimable, developments in, or the ultimate resolution of, a matter could be material to the Company and could have a material adverse effect on the Company, its consolidated financial position, results of operations and cash flows. In addition, future adverse rulings or developments, or settlements in, one or more matters could result in future changes to determinations of probable and reasonably estimable losses in other matters. Process for Disclosure and Recording of Insurance Receivables Related to Legal Proceedings: The Company estimates insurance receivables based on an analysis of the terms of its numerous policies, including their exclusions, pertinent case law interpreting comparable policies, its experience with similar claims, and assessment of the nature of the claim and remaining coverage, and records an amount it has concluded is recognizable and expects to receive in light of the loss recovery and/or gain contingency models under ASC 450, ASC 610-30, and related guidance. For those insured legal proceedings where the Company has recorded an accrued liability in its financial statements, the Company also records receivables for the amount of insurance that it concludes as recognizable from the Company’s insurance program. For those insured matters where the Company has not recorded an accrued liability because the liability is not probable or the amount of the liability is not estimable, or both, but where the Company has incurred an expense in defending itself, the Company records receivables for the amount of insurance that it concludes as recognizable for the expense incurred. Impact of Solventum Spin-Off : On April 1, 2024, the Company completed the planned spin-off of its Health Care business, known as Solventum, as an independent company. Concurrent with the spin-off, the Company and Solventum entered into various agreements, including transition agreements and a separation and distribution agreement that, among other things, identified the assets to be transferred, the liabilities to be assumed, indemnification and defense obligations, and the contracts to be transferred to Solventum and 3M as part of the spin-off. In general, and except as noted below and as set forth in the separation and distribution agreement, certain liabilities related to Solventum or the assets that are transferred to Solventum in connection with the spin-off will be retained by or transferred to Solventum. For example, potential liabilities associated with the matters previously described under the Bair Hugger and Federal False Claims Act / Qui Tam Litigation sections of this Note 17 have been assumed by Solventum pursuant to the separation and distribution agreement, and Solventum will indemnify and defend the Company in these actions. The separation and distribution agreement governs the allocation of liabilities related to PFAS (as defined below) between the Company and Solventum, which liabilities will not be subject to the general allocation principles otherwise set forth in the separation and distribution agreement. The Company will retain all PFAS-related liabilities resulting from the business, operations, and activities of (x) the Company’s business (as defined in the separation and distribution agreement) and (y) Solventum’s business (as defined in the separation and distribution agreement) prior to April 1, 2024. Solventum will retain liability for all PFAS-related liabilities resulting from the business, operations, and activities of its business at or after April 1, 2024, other than liabilities from product claims alleging harm from the presence of PFAS in certain products of Solventum’s business sold at or after April 1, 2024, and prior to January 1, 2026 (subject to exceptions described in further detail below). The Company will retain liabilities related to site-based PFAS contamination at any real property owned, leased or operated by the Company and liabilities for site-based PFAS contamination arising from third-party claims at sites allocated to the Solventum group in the separation to the extent such liabilities relate to PFAS contamination existing at or prior to April 1, 2024. Solventum assumes PFAS liabilities from the Solventum sites to the extent resulting from an action taken by any member of the Solventum group following April 1, 2024 or from any failure by Solventum following April 1, 2024, to use commercially reasonable efforts that are consistent with then-current industry standards to avoid contamination. The Company will also retain PFAS liabilities for product claims (x) arising from the Company’s products, (y) arising from Solventum’s products sold prior to April 1, 2024, and (z) arising from certain products sold by Solventum at or after April 1, 2024, and prior to January 1, 2026 (subject to the exceptions described below). Clause (z) in the immediately preceding sentence will not extend to PFAS liabilities for product claims resulting from (i) new products introduced by Solventum following April 1, 2024, that contain or are enabled by PFAS that is not supplied by the Company, (ii) products that are modified by Solventum after April 1, 2024, to add, contain or become enabled by PFAS that is not supplied by the Company, or with respect to which any modification made after April 1, 2024, in the formulation or production of the product that changes the amount or type of PFAS contained in the product or the amount or type of PFAS enabling the product, in each case from and after the date of such modification, (iii) PFAS that is added to a Solventum product after it is sold by Solventum and (iv) PFAS that has accumulated in or on a Solventum product as a result of the use of the product (whether or not the product is being used as directed), including through filtration, purification or similar application. Solventum will be responsible for the maintenance of certain PFAS containment measures at its properties after the effective time of the distribution. In addition, and consistent with the allocation described above, the Company will retain specifically identified PFAS-related liabilities, including those resulting from specified PFAS-related litigation matters and liabilities under the Company’s settlement agreement with public water systems in the United States, as described below. The following sections first describe the significant legal proceedings in which the Company is involved, and then describe the liabilities and associated insurance receivables the Company has accrued relating to its significant legal proceedings. Respirator Mask/Asbestos Litigation: As of June 30, 2024, the Company is a named defendant, with multiple co-defendants, in numerous lawsuits in various courts that purport to represent approximately 4,106 individual claimants, compared to approximately 4,060 individual claimants with actions pending March 31, 2024. The vast majority of the lawsuits and claims resolved by and currently pending against the Company allege use of some of the Company’s mask and respirator products and seek damages from the Company and other defendants for alleged personal injury from workplace exposures to asbestos, silica, coal mine dust or other occupational dusts found in products manufactured by other defendants or generally in the workplace. A minority of the lawsuits and claims resolved by and currently pending against the Company generally allege personal injury from occupational exposure to asbestos from products previously manufactured by the Company, which are often unspecified, as well as products manufactured by other defendants, or occasionally at Company premises. The Company’s current volume of new and pending matters is substantially lower than it experienced at the peak of filings in 2003. The Company expects that the filing of claims in the future will continue to be at much lower levels than in the past. Accordingly, the number of claims alleging more serious injuries, including mesothelioma, other malignancies, and black lung disease, will represent a greater percentage of total claims than in the past. Over the past twenty The Company has demonstrated in these past trial proceedings that its respiratory protection products are effective as claimed when used in the intended manner and in the intended circumstances. Consequently, the Company believes that claimants are unable to establish that their medical conditions, even if significant, are attributable to the Company’s respiratory protection products. Nonetheless, the Company’s litigation experience indicates that claims of persons alleging more serious injuries, including mesothelioma, other malignancies, and black lung disease, are costlier to resolve than the claims of unimpaired persons, and it therefore believes the average cost of resolving pending and future claims on a per-claim basis will continue to be higher than it experienced in prior periods when the vast majority of claims were asserted by medically unimpaired claimants. In the second half of 2020 and into 2021, the Company experienced an increase in the number of cases filed that allege injuries from exposures to coal mine dust, but the rate of coal mine dust-related case filings decelerated in 2022 and continues to stay significantly lower than in 2021. 3M moved two cases involving over 400 plaintiffs to federal court based on, among others, the Class Action Fairness Act. The federal district court remanded the cases to state court. In March 2023, the Sixth Circuit Court of Appeals granted 3M's petition to review the remand order, and in April 2023 reversed the district court's remand order; accordingly, those cases will remain in federal court. As previously reported, the State of West Virginia, through its Attorney General, filed a complaint in 2003 against the Company and two other manufacturers of respiratory protection products in the Circuit Court of Lincoln County, West Virginia, and amended its complaint in 2005. The amended complaint seeks substantial, but unspecified, compensatory damages primarily for reimbursement of the costs allegedly incurred by the State for worker’s compensation and healthcare benefits provided to all workers with occupational pneumoconiosis and unspecified punitive damages. In October 2019, the court granted the State’s motion to sever its unfair trade practices claim, which seeks civil penalties of up to $5,000 per violation under the state's Consumer Credit Protection Act relating to statements that the State contends were misleading about 3M’s respirators. In April 2024, the court set a trial date for the unfair trade practices claims in December 2024. An expert witness retained by the State has estimated that 3M sold over five million respirators into the state during the relevant time period, and the State alleges that each respirator sold constitutes a separate violation under the Act. 3M disputes the expert's estimates and the State's position regarding what constitutes a separate violation of the Act. 3M has asserted various additional defenses, including that the Company's marketing did not violate the Act at any time, and that the State's claims are barred under the applicable statute of limitations. No liability has been recorded for any portion of this matter because the Company believes that liability is not probable and reasonably estimable at this time. In addition, the Company is not able to estimate a possible loss or range of loss given the lack of any meaningful discovery responses by the State of West Virginia as to key issues, and the assertions of claims against two other manufacturers where a defendant’s share of liability may turn on the law of joint and several liability and by the amount of fault, if any, a factfinder may allocate to each defendant if the case were ultimately tried. Respirator Mask/Asbestos Liabilities and Insurance Receivables The Company regularly conducts a comprehensive legal review of its respirator mask/asbestos liabilities. The Company reviews recent and historical claims data, including without limitation, (i) the number of pending claims filed against the Company, (ii) the nature and mix of those claims (i.e., the proportion of claims asserting usage of the Company’s mask or respirator products and alleging exposure to each of asbestos, silica, coal or other occupational dusts, and claims pleading use of asbestos-containing products allegedly manufactured by the Company), (iii) the costs to defend and resolve pending claims, and (iv) trends in filing rates and in costs to defend and resolve claims (collectively, the “Claims Data”). As part of its comprehensive legal review, the Company regularly provides the Claims Data to a third party with expertise in determining the impact of Claims Data on future filing trends and costs. The third party assists the Company in estimating the costs to defend and resolve pending and future claims. The Company uses this analysis to develop its estimate of probable liability. Developments may occur that could affect the Company’s estimate of its liabilities. These developments include, but are not limited to, significant changes in (i) the key assumptions underlying the Company’s accrual, including the number of future claims, the nature and mix of those claims, and the average cost of defending and resolving claims and in maintaining trial readiness (ii) trial and appellate outcomes, (iii) the law and procedure applicable to these claims, and (iv) the financial viability of other co-defendants and insurers. As a result of its review of its respirator mask/asbestos liabilities, of pending and expected lawsuits and of the cost of resolving claims of persons who claim more serious injuries, including mesothelioma, other malignancies, and black lung disease, the Company increased its accruals in the first six months of 2024 for respirator mask/asbestos liabilities by $19 million. In the first six months of 2024, the Company made payments for legal defense costs and settlements of $41 million related to the respirator mask/asbestos litigation. As of June 30, 2024, the Company had an accrual for respirator mask/asbestos liabilities (excluding Aearo accruals) of $552 million. This accrual represents the Company’s estimate of probable loss and reflects an estimation period for future claims that may be filed against the Company approaching the year 2050. The Company cannot estimate the amount or upper end of the range of amounts by which the liability may exceed the accrual the Company has established because of (i) the inherent difficulty in projecting the number of claims that have not yet been asserted or the time period in which future claims may be asserted, (ii) the fact that complaints nearly always assert claims against multiple defendants where the damages alleged are typically not attributed to individual defendants so that a defendant’s share of liability may turn on the law of joint and several liability, which can vary by state, (iii) the multiple factors described above that the Company considers in estimating its liabilities, and (iv) the several possible developments described above that may occur that could affect the Company’s estimate of liabilities. As of June 30, 2024, the Company had an immaterial receivable for insurance recoveries related to the respirator mask/asbestos litigation. In addition, the Company continues to seek coverage under the policies of certain insolvent and other insurers. Once those claims for coverage are resolved, the Company will have collected substantially all of its remaining insurance coverage for respirator mask/asbestos claims. Respirator Mask/Asbestos Litigation — Aearo Technologies: On April 1, 2008, a subsidiary of the Company acquired the stock of Aearo Holding Corp., the parent of Aearo Technologies (“Aearo”). Aearo manufactured and sold various products, including personal protection equipment, such as eye, ear, head, face, fall and certain respiratory protection products. Aearo and/or other companies that previously owned and operated Aearo’s respirator business (American Optical Corporation, Warner-Lambert LLC, AO Corp. and Cabot Corporation (“Cabot”)) are named defendants, with multiple co-defendants, including the Company, in numerous lawsuits in various courts in which plaintiffs allege use of mask and respirator products and seek damages from Aearo and other defendants for alleged personal injury from workplace exposures to asbestos, silica-related, coal mine dust, or other occupational dusts found in products manufactured by other defendants or generally in the workplace. In July 2022, Aearo Technologies and certain of its related entities (collectively, the "Aearo Entities") voluntarily initiated chapter 11 proceedings under the U.S. Bankruptcy Code seeking court supervision to establish a trust, funded by the Company, to efficiently and equitably satisfy all claims determined to be entitled to compensation (including the Aearo respirator mask/asbestos matters). The U.S. Bankruptcy Court had stayed the Aearo respirator mask/asbestos litigation matters during the chapter 11 proceedings. During the voluntary chapter 11 proceedings, 3M's accrual relating to the commitments associated with funding that trust included Aearo respirator mask/asbestos matters. With the June 2023 dismissal of the Aearo bankruptcy that is described in the Product Liability Litigation section below, the stay of respirator mask/asbestos litigation is no longer in effect. For additional information, see the discussion within the section Product Liability Litigation with respect to Aearo Technologies Dual-Ended Combat Arms Earplugs. As of June 30, 2024, the Company, through its Aearo subsidiary, had accruals of $53 million for product liabilities and defense costs related to current and future Aearo-related asbestos, silica-related and coal mine dust claims. Responsibility for legal costs, as well as for settlements and judgments, is shared in an informal arrangement among Aearo, Cabot, American Optical Corporation and a subsidiary of Warner Lambert and their respective insurers (the “Payor Group”). Liability is allocated among the parties based on the number of years each company sold respiratory products under the “AO Safety” brand and/or owned the AO Safety Division of American Optical Corporation and the alleged years of exposure of the individual plaintiff. Aearo’s share of the contingent liability is further limited by an agreement entered into between Aearo and Cabot on July 11, 1995. This agreement provides that, so long as Aearo pays to Cabot a quarterly fee of $100,000, Cabot will retain responsibility and liability for, and indemnify Aearo against, any product liability claims involving exposure to asbestos, silica, or silica products for respirators sold prior to July 11, 1995. Because of the difficulty in determining how long a particular respirator remains in the stream of commerce after being sold, Aearo and Cabot have applied the agreement to claims arising out of the alleged use of respirators involving exposure to asbestos, silica or silica products prior to January 1, 1997. With these arrangements in place, Aearo’s potential liability is limited to exposures alleged to have arisen from the use of respirators involving exposure to asbestos, silica, or silica products on or after January 1, 1997. To date, Aearo has elected to pay the quarterly fee. Aearo could potentially be exposed to additional claims for some part of the pre-July 11, 1995, period covered by its agreement with Cabot if Aearo elects to discontinue its participation in this arrangement, or if Cabot is no longer able to meet its obligations in these matters. Developments may occur that could affect the estimate of Aearo’s liabilities. These developments include, but are not limited to: (i) significant changes in the number of future claims, (ii) significant changes in the average cost of resolving claims, (iii) significant changes in the legal costs of defending these claims, (iv) significant changes in the mix and nature of claims received, (v) trial and appellate outcomes, (vi) significant changes in the law and procedure applicable to these claims, (vii) significant changes in the liability allocation among the co-defendants, (viii) the financial viability of members of the Payor Group including exhaustion of available insurance coverage limits, and/or (ix) a determination that the interpretation of the contractual obligations on which Aearo has estimated its share of liability is inaccurate. The Company cannot determine the impact of these potential developments on its current estimate of Aearo’s share of liability for these existing and future claims. If any of the developments described above were to occur, the actual amount of these liabilities for existing and future claims could be significantly larger than the amount accrued. Because of the inherent difficulty in projecting the number of claims that have not yet been asserted, the complexity of allocating responsibility for future claims among the Payor Group, and the several possible developments that may occur that could affect the estimate of Aearo’s liabilities, the Company cannot estimate the amount or range of amounts by which Aearo’s liability may exceed the accrual the Company has established. Environmental Matters and Litigation: The Company’s operations are subject to environmental laws and regulations including those pertaining to air emissions, wastewater discharges, toxic or hazardous substances, and the handling and disposal of solid and hazardous wastes, which are enforceable by national, state, and local authorities around the world, and many for which private parties in the United States and abroad may have rights of action. These laws and regulations can form the basis of, under certain circumstances, claims for the investigation and remediation of contamination, for capital investment in pollution control equipment, for restoration of and/or compensation for damages to natural resources, and for personal injury and property damages. The Company has incurred, and will continue to incur, costs and capital expenditures in complying with these laws and regulations, defending personal injury, natural resource, and property damage claims, and modifying its business operations in light of its environmental responsibilities. In its effort to satisfy its environmental responsibilities and comply with environmental laws and regulations, the Company has established, and periodically updates, policies relating to environmental standards of performance for its operations worldwide. Under certain environmental laws, including the United States Comprehensive Environmental Response, Compensation and Liability Act of 1980 ("CERCLA") and similar state laws, the Company may be jointly and severally liable, sometimes with other potentially responsible parties, for the costs of investigation and remediation of environmental contamination at current or former facilities and at off-site locations where hazardous substances have been released or disposed of. The Company has identified numerous locations, many of which are in the United States, at which it may have some liability for remediation of contamination under applicable environmental laws. Please refer to the section entitled “ Environmental Liabilities and Insurance Receivables” that follows for information on the amount of the accrual for such liabilities. Environmental Matters As previously reported, the Company has been voluntarily cooperating with ongoing reviews by local, state, federal (primarily the U.S. Environmental Protection Agency ("EPA")), and international agencies of possible environmental and health effects of various perfluorinated compounds, including perfluorooctanoate ("PFOA"), perfluorooctane sulfonate ("PFOS"), perfluorohexane sulfonic acid ("PFHxS"), perfluorobutane sulfonate ("PFBS"), hexafluoropropylene oxide dimer acid ("HFPO-DA") and other per- and polyfluoroalkyl substances (collectively, "PFAS"). As a result of a phase-out decision in May 2000, the Company no longer manufactures certain PFAS compounds including PFOA, PFOS, PFHxS, and their precursor compounds. The Company ceased manufacturing and using the vast majority of those compounds within approximately two years of the phase-out announcement and ceased all manufacturing and the last significant use of those compounds by the end of 2008. The Company continues to manufacture a variety of shorter chain length PFAS compounds. These compounds are used as input materials to a variety of products, including engineered fluorinated fluids, fluoropolymers and fluorelastomers, as well as surfactants, additives, and coatings. Through its ongoing life cycle management and its raw material composition identification processes associated with the Company’s policies covering the use of all persistent and bio-accumulative materials, the Company continues to review, control or eliminate the presence of certain PFAS in purchased materials, as intended substances in products, or as byproducts in some of 3M’s current manufacturing processes, products, and waste streams. 3M announced in December 2022 it will take two actions with respect to PFAS: exiting all PFAS manufacturing by the end of 2025; and working to discontinue the use of PFAS across its product portfolio by the end of 2025. 3M is progressing toward the exit of all PFAS manufacturing by the end of 2025. 3M is also working to discontinue the use of PFAS across its product portfolio by the end of 2025 and has made progress in eliminating the use of PFAS across its product portfolio in a variety of applications. With respect to PFAS-containing products not manufactured by 3M in the Company's supply chains, the Company continues to evaluate the availability and feasibility of third-party products that do not contain PFAS. Depending on the availability and feasibility of such third-party products not containing PFAS, the Company continues to evaluate circumstances in which the use of PFAS-containing products manufactured by third parties and used in certain applications in 3M’s product portfolios, such as lithium ion batteries, printed circuit boards and certain seals and gaskets, all widely used in commerce across a variety of industries, and in some cases required by regulatory or industry standards, may or are expected to, depending on applications, continue beyond 2025. In other cases, regulatory approval, customer re-certification or re-qualification of substitutes or replacements to eliminate the use of PFAS manufactured by third parties may not be completed, or, depending on circumstances, are not expected to be completed, by the end of 2025. With respect to PFAS-containing produc

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	NOTE 18. Stock-Based Compensation The Company’s annual stock option and restricted stock unit grant is typically made in February to provide a strong and immediate link between the performance of individuals during the preceding year and the size of their annual stock compensation grants. The grant to eligible employees uses the closing stock price on the grant date. Accounting rules require recognition of expense under a non-substantive vesting period approach, requiring compensation expense recognition when an employee is eligible to retire. Employees are considered eligible to retire at age 55 and after having completed ten years of service. This retiree-eligible population represents 34 percent of the annual grant stock-based compensation expense; therefore, higher stock-based compensation expense is typically recognized in the first quarter. However, due to the spin-off of Solventum (see Note 2), the 2024 annual grant was made in May, after the April 1, 2024 separation. In addition to the annual grants, the Company makes other minor grants of stock options, restricted stock units and other stock-based grants. The Company issues cash settled restricted stock units and stock appreciation rights in certain countries. The cash settled grants do not result in the issuance of common stock and are considered immaterial by the Company, and not included in the tables below. In connection with the Solventum separation on April 1, 2024 (see Note 2), all outstanding stock-based compensation awards associated with Solventum employees converted into Solventum awards, became Solventum’s responsibility and were cancelled from 3M plans. The conversion into Solventum awards was made with the intent to preserve the intrinsic value of each award immediately before and after the Separation. In addition, for awards associated with remaining 3M employees, the number of shares underlying unvested stock awards was adjusted along with the exercise price and the number of shares underlying outstanding stock options. These adjustments were made with the intent to preserve the intrinsic value of each award immediately before and after the Separation and were determined using a ratio calculated using the 3M share price based on the market closing price before and the average of the closing price from the first three days of trading after the Separation. The terms of the outstanding awards remain the same and if unvested, continue to vest over the original vesting periods. The adjustments to shares underlying unvested stock awards and outstanding stock options did not result in a material stock-based compensation cost. Stock-Based Compensation Expense: Amounts recognized in the financial statements with respect to stock-based compensation programs, which include stock options, restricted stock, restricted stock units, performance shares and the General Employees’ Stock Purchase Plan (GESPP), are provided in the following table. Capitalized stock-based compensation amounts were not material. Three months ended Six months ended (Millions) 2024 2023 2024 2023 Cost of sales $ 19 $ 8 $ 24 $ 26 Selling, general and administrative expenses 107 21 125 100 Research, development and related expenses 28 6 31 29 Stock-based compensation expenses 154 35 180 155 Income tax benefits (33) (4) (14) (28) Stock-based compensation expenses (benefits), net of tax $ 121 $ 31 $ 166 $ 127

Business Segments

Business Segments	6 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
Business Segments	NOTE 19. Business Segments 3M’s businesses are organized, managed and internally grouped into segments based on differences in markets, products, technologies and services. 3M manages its operations in three business segments: Safety and Industrial; Transportation and Electronics; and Consumer. 3M’s three business segments bring together common or related 3M technologies, enhancing the development of innovative products and services and providing for efficient sharing of business resources. On April 1, 2024, 3M completed the previously announced separation of its Health Care business as a separate public company, Solventum (see Note 2 for additional information). 3M is an integrated enterprise characterized by substantial intersegment cooperation, cost allocations and inventory transfers. Therefore, management does not represent that these segments, if operated independently, would report the operating income information shown. 3M discloses business segment operating income (loss) as its measure of segment profit/loss, reconciled to both total 3M operating income (loss) and income before taxes. Business segment operating income (loss) excludes certain expenses and income that are not allocated to business segments (as described below in “Corporate and Unallocated and Other”). 3M made certain changes to the composition of segment information reviewed by 3M's chief operating decision maker (CODM) effective in the second quarter of 2024 largely as a result of the separation of Solventum and changes within its business segments effective in the first quarter of 2024. Accordingly, information provided herein reflects the impact of these changes for all applicable periods presented. Effective in the second quarter of 2024, this change included the following: Elimination of former Health Care business segment • The former Health Care business segment was eliminated in the second quarter of 2024 in connection with the separation of Solventum and reflection of its historical net income and applicable assets and liabilities included in the Separation as discontinued operations within 3M's financial statements. Addition of ‘Other’ and update to ‘Corporate and Unallocated’ • 3M added the “Other” category of information as a result of the Separation. It principally reflects activity associated with: ◦ Transition arrangement agreements (e.g. fees charged by 3M, net of underlying costs) related to divested businesses, including those related to the Separation, as well as other applicable divestitures. ◦ Operations of businesses of the former Health Care segment divested prior to the Separation and therefore not reflected as discontinued operations within 3M's financial statements, along with limited-duration supply agreements with those previous divestitures. • Activity included in 3M’s existing “Corporate and Unallocated” was updated primarily to additionally reflect: ◦ Removal of costs related to separating and divesting Solventum that were eligible to be part of discontinued operations. ◦ Commercial activity with Solventum post-Separation and certain operations of the former Health Care business segment retained by 3M. ◦ Costs previously allocated to Solventum prior to the Separation that were not eligible to be part of discontinued operations other than those beginning in the first quarter of 2024 included in “Other” associated with transition arrangement activity for which 3M began to charge fees in April 2024. In addition, effective in the first quarter of 2024, 3M made certain changes within its business segments as described below. While they impacted the composition of certain divisions within business segments, they did not change the overall composition of segments or the measure of segment operating performance used by 3M’s CODM. Creation of Industrial Specialties division (within Safety and Industrial business segment) and Commercial Branding and Transportation division (within Transportation and Electronics business segment) • 3M created the Industrial Specialties division within the Safety and Industrial business segment, which consists of the former Closure and Masking Systems division along with certain products formerly within the Industrial Adhesive and Tapes division and the Personal Safety division. Further, 3M created the Commercial Branding and Transportation division within the Transportation and Electronics business segment, which consists of the former Commercial Solutions division and the Transportation Safety division. Re-alignment of divisions within Consumer business segment • Within the Consumer business segment, the business re-aligned to the following four divisions: Consumer Safety and Well-Being, Home and Auto Care, Home Improvement, and Packaging and Expression. Business Segment Information Three months ended Six months ended Net Sales (Millions) 2024 2023 2024 2023 Safety and Industrial $ 2,759 $ 2,765 $ 5,491 $ 5,544 Transportation and Electronics 2,143 2,191 4,247 4,241 Consumer 1,263 1,293 2,403 2,485 Corporate and Unallocated 86 22 112 45 Other 4 12 18 23 Total Company $ 6,255 $ 6,283 $ 12,271 $ 12,338 Operating Performance (Millions) - income (loss) Safety and Industrial $ 612 $ 534 $ 1,269 $ 1,135 Transportation and Electronics 428 410 909 704 Consumer 219 235 435 414 Corporate and Unallocated Corporate special items: Net costs for significant litigation (8) (10,357) (71) (10,439) Divestiture costs (14) (1) (20) (4) Russia exit (charges) benefits — 18 — 18 Total corporate special items (22) (10,340) (91) (10,425) Other corporate (expense) income - net (2) (207) (73) (339) Total Corporate and Unallocated (24) (10,547) (164) (10,764) Other 37 10 (28) 19 Total Company operating income (loss) 1,272 (9,358) 2,421 (8,492) Other expense/(income), net (138) 72 82 128 Income (loss) before income taxes $ 1,410 $ (9,430) $ 2,339 $ (8,620) Corporate and Unallocated and Other: Outside of 3M's operating segments, 3M has Corporate and Unallocated and Other which are not reportable business segments as they do not meet the segment reporting criteria. Because Corporate and Unallocated and Other includes a variety of miscellaneous items, it is subject to fluctuation on a quarterly and annual basis. • Corporate and Unallocated operating income (loss) includes “corporate special items” and “other corporate expense-net”. ◦ Corporate special items include net costs for significant litigation impacting operating income (loss) associated with PFAS-related other environmental and Combat Arms Earplugs matters. In addition, during the voluntary chapter 11 bankruptcy period (which began in July 2022 and ended in June 2023—see Note 17), costs associated with the Aearo portion of respirator mask/asbestos matters were also included in corporate special items. Prior to the bankruptcy, costs associated with Combat Arms Earplugs matters were not included in the Corporate net costs for significant litigation special item, instead being reflected in the Safety and Industrial business segment. Corporate special items for the periods presented also include divestiture costs and Russia exit costs/ benefits. Divestiture costs include costs that were not eligible to be part of discontinued operations related to separating and divesting substantially an entire business segment of 3M following public announcement of its intended divestiture. ◦ Other corporate expense-net includes certain enterprise and governance activities resulting in unallocated corporate costs and other activity and net costs that 3M may choose not to allocate directly to its business segments. Other corporate expense-net also includes costs previously allocated to Solventum prior to the Separation that were not eligible to be part of discontinued operations, commercial activity with Solventum post-Separation, and certain operations of the former Health Care business segment retained by 3M. • Other principally reflects activity associated with: ◦ Operations of businesses of the former Health Care segment divested prior to the Separation and therefore not reflected as discontinued operations within 3M's financial statements, along with limited-duration supply agreements with those previous divestitures. ◦ Transition arrangement agreements (e.g. fees charged by 3M, net of underlying costs) related to divested businesses, including those related to the Separation, as well as other applicable divestitures.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ 1,145	$ (6,841)	$ 2,073	$ (5,865)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation:
New Accounting Pronouncements	New Accounting Pronouncements: Refer to Note 1 to the Consolidated Financial Statements in 3M's 2023 Annual Report on Form 10-K for a discussion of applicable standards issued and not yet adopted by 3M. Relevant New Standards Issued Subsequent to Most Recent Annual Report In March 2024, the SEC adopted rules under SEC Release No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors , which require a registrant to disclose information in annual reports and registration statements about climate-related risks that are reasonably likely to have a material impact on its business, results of operations, or financial condition. The information would include disclosure of a registrant's greenhouse gas emissions. In addition, certain disclosures related to severe weather events and other natural conditions will be required in a registrant’s audited financial statements. Annual disclosure requirements would be effective for 3M as early as the fiscal year beginning January 1, 2025. However, in April 2024, the SEC voluntarily stayed the final rules pending certain legal challenges. The Company is evaluating the impact of these rules on its disclosures.
Earnings (Loss) Per Share	The difference in the weighted average 3M shares outstanding for calculating basic and diluted earnings per share attributable to 3M common shareholders is the result of the dilution associated with the Company’s stock-based compensation plans. Certain awards outstanding under these stock-based compensation plans were not included in the computation of diluted earnings per share attributable to 3M common shareholders because they would have had an anti-dilutive effect of 33.1 million and 32.9 million average options for the three and six months ended June 30, 2024, respectively, and 36.9 million and 36.5 million average options for the three and six months ended June 30, 2023, respectively. In periods of net losses, these anti-dilutive effects include all weighted option shares outstanding and weighted average shares is the same for the calculations of both basic and diluted loss per share.
Legal Proceedings	Process for Disclosure and Recording of Liabilities Related to Legal Proceedings: Many lawsuits and claims involve highly complex issues relating to causation, scientific evidence, and alleged actual damages, all of which are otherwise subject to substantial uncertainties. Assessments of lawsuits and claims can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. The categories of legal proceedings in which the Company is involved may include multiple lawsuits and claims, may be spread across multiple jurisdictions and courts which may handle the lawsuits and claims differently, may involve numerous and different types of plaintiffs, raising claims and legal theories based on specific allegations that may not apply to other matters, and may seek substantial compensatory and, in some cases, punitive, damages. These and other factors contribute to the complexity of these lawsuits and claims and make it difficult for the Company to predict outcomes and make reasonable estimates of any resulting losses. The Company's ability to predict outcomes and make reasonable estimates of potential losses is further influenced by the fact that a resolution of one or more matters within a category of legal proceedings may impact the resolution of other matters in that category in terms of timing, amount of liability, or both. When making determinations about recording liabilities related to legal proceedings, the Company complies with the requirements of ASC 450, Contingencies, and related guidance, and records liabilities in those instances where it can reasonably estimate the amount of the loss and when the loss is probable. Where the reasonable estimate of the probable loss is a range, the Company records as an accrual in its financial statements the most likely estimate of the loss, or the low end of the range if there is no one best estimate. The Company either discloses the amount of a possible loss or range of loss in excess of established accruals if estimable, or states that such an estimate cannot be made. The Company discloses significant legal proceedings even where liability is not probable or the amount of the liability is not estimable, or both, if the Company believes there is at least a reasonable possibility that a loss may be incurred. Based on experience and developments, the Company reexamines its estimates of probable liabilities and associated expenses and receivables each period, and whether a loss previously determined to not be reasonably estimable and/or not probable is now able to be reasonably estimated or has become probable. Where appropriate, the Company makes additions to or adjustments of its reasonably estimated losses and/or accruals. As a result, the current accruals and/or estimates of loss and the estimates of the potential impact on the Company’s consolidated financial position, results of operations and cash flows for the legal proceedings and claims pending against the Company will likely change over time. Because litigation is subject to inherent uncertainties, and unfavorable rulings or developments could occur, the Company may ultimately incur charges substantially in excess of presently recorded liabilities, including with respect to matters for which no accruals are currently recorded because losses are not currently probable and reasonably estimable. Many of the matters described herein are at varying stages, seek an indeterminate amount of damages or seek damages in amounts that the Company believes are not indicative of the ultimate losses that may be incurred. It is not uncommon for claims to be resolved over many years. As a matter progresses, the Company may receive information, through plaintiff demands, through discovery, in the form of reports of purported experts, or in the context of settlement or mediation discussions that purport to quantify an amount of alleged damages, but with which the Company may not agree. Such information may or may not lead the Company to determine that it is able to make a reasonable estimate as to a probable loss or range of loss in connection with a matter. However, even when a loss or range of loss is not probable and reasonably estimable, developments in, or the ultimate resolution of, a matter could be material to the Company and could have a material adverse effect on the Company, its consolidated financial position, results of operations and cash flows. In addition, future adverse rulings or developments, or settlements in, one or more matters could result in future changes to determinations of probable and reasonably estimable losses in other matters. Process for Disclosure and Recording of Insurance Receivables Related to Legal Proceedings: The Company estimates insurance receivables based on an analysis of the terms of its numerous policies, including their exclusions, pertinent case law interpreting comparable policies, its experience with similar claims, and assessment of the nature of the claim and remaining coverage, and records an amount it has concluded is recognizable and expects to receive in light of the loss recovery and/or gain contingency models under ASC 450, ASC 610-30, and related guidance. For those insured legal proceedings where the Company has recorded an accrued liability in its financial statements, the Company also records receivables for the amount of insurance that it concludes as recognizable from the Company’s insurance program. For those insured matters where the Company has not recorded an accrued liability because the liability is not probable or the amount of the liability is not estimable, or both, but where the Company has incurred an expense in defending itself, the Company records receivables for the amount of insurance that it concludes as recognizable for the expense incurred.
Business Segments	3M’s businesses are organized, managed and internally grouped into segments based on differences in markets, products, technologies and services. 3M manages its operations in three business segments: Safety and Industrial; Transportation and Electronics; and Consumer. 3M’s three business segments bring together common or related 3M technologies, enhancing the development of innovative products and services and providing for efficient sharing of business resources. On April 1, 2024, 3M completed the previously announced separation of its Health Care business as a separate public company, Solventum (see Note 2 for additional information). 3M is an integrated enterprise characterized by substantial intersegment cooperation, cost allocations and inventory transfers. Therefore, management does not represent that these segments, if operated independently, would report the operating income information shown. 3M discloses business segment operating income (loss) as its measure of segment profit/loss, reconciled to both total 3M operating income (loss) and income before taxes. Business segment operating income (loss) excludes certain expenses and income that are not allocated to business segments (as described below in “Corporate and Unallocated and Other”). 3M made certain changes to the composition of segment information reviewed by 3M's chief operating decision maker (CODM) effective in the second quarter of 2024 largely as a result of the separation of Solventum and changes within its business segments effective in the first quarter of 2024. Accordingly, information provided herein reflects the impact of these changes for all applicable periods presented. Effective in the second quarter of 2024, this change included the following: Elimination of former Health Care business segment • The former Health Care business segment was eliminated in the second quarter of 2024 in connection with the separation of Solventum and reflection of its historical net income and applicable assets and liabilities included in the Separation as discontinued operations within 3M's financial statements. Addition of ‘Other’ and update to ‘Corporate and Unallocated’ • 3M added the “Other” category of information as a result of the Separation. It principally reflects activity associated with: ◦ Transition arrangement agreements (e.g. fees charged by 3M, net of underlying costs) related to divested businesses, including those related to the Separation, as well as other applicable divestitures. ◦ Operations of businesses of the former Health Care segment divested prior to the Separation and therefore not reflected as discontinued operations within 3M's financial statements, along with limited-duration supply agreements with those previous divestitures. • Activity included in 3M’s existing “Corporate and Unallocated” was updated primarily to additionally reflect: ◦ Removal of costs related to separating and divesting Solventum that were eligible to be part of discontinued operations. ◦ Commercial activity with Solventum post-Separation and certain operations of the former Health Care business segment retained by 3M. ◦ Costs previously allocated to Solventum prior to the Separation that were not eligible to be part of discontinued operations other than those beginning in the first quarter of 2024 included in “Other” associated with transition arrangement activity for which 3M began to charge fees in April 2024. Corporate and Unallocated and Other: Outside of 3M's operating segments, 3M has Corporate and Unallocated and Other which are not reportable business segments as they do not meet the segment reporting criteria. Because Corporate and Unallocated and Other includes a variety of miscellaneous items, it is subject to fluctuation on a quarterly and annual basis. • Corporate and Unallocated operating income (loss) includes “corporate special items” and “other corporate expense-net”. ◦ Corporate special items include net costs for significant litigation impacting operating income (loss) associated with PFAS-related other environmental and Combat Arms Earplugs matters. In addition, during the voluntary chapter 11 bankruptcy period (which began in July 2022 and ended in June 2023—see Note 17), costs associated with the Aearo portion of respirator mask/asbestos matters were also included in corporate special items. Prior to the bankruptcy, costs associated with Combat Arms Earplugs matters were not included in the Corporate net costs for significant litigation special item, instead being reflected in the Safety and Industrial business segment. Corporate special items for the periods presented also include divestiture costs and Russia exit costs/ benefits. Divestiture costs include costs that were not eligible to be part of discontinued operations related to separating and divesting substantially an entire business segment of 3M following public announcement of its intended divestiture. ◦ Other corporate expense-net includes certain enterprise and governance activities resulting in unallocated corporate costs and other activity and net costs that 3M may choose not to allocate directly to its business segments. Other corporate expense-net also includes costs previously allocated to Solventum prior to the Separation that were not eligible to be part of discontinued operations, commercial activity with Solventum post-Separation, and certain operations of the former Health Care business segment retained by 3M. • Other principally reflects activity associated with: ◦ Operations of businesses of the former Health Care segment divested prior to the Separation and therefore not reflected as discontinued operations within 3M's financial statements, along with limited-duration supply agreements with those previous divestitures. ◦ Transition arrangement agreements (e.g. fees charged by 3M, net of underlying costs) related to divested businesses, including those related to the Separation, as well as other applicable divestitures.

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Disposal Groups, Including Discontinued Operations	Information regarding net income (loss) from discontinued operations, net of taxes includes the following: Three months ended Six months ended Net Income (Loss) from Discontinued Operations, Net of Taxes (millions) 2024 2023 2024 2023 Net sales $ — $ 2,042 $ 1,987 $ 4,018 Cost of sales — 878 844 1,747 Other operating expenses 46 764 837 1,496 Other expense (income), net — (7) 44 (11) Income (loss) from discontinued operations before income taxes (46) 407 262 786 Provision for income taxes 13 77 98 142 Net income (loss) from discontinued operations, net of taxes $ (59) $ 330 $ 164 $ 644 Major classes of assets and liabilities of discontinued operations include the following: Assets and Liabilities of Discontinued Operations (millions) December 31, 2023 Assets Cash and cash equivalents $ 198 Marketable securities — current 3 Accounts receivable — net 1,149 Inventories 878 Other current assets 151 Current assets of discontinued operations 2,379 Property, plant and equipment — net 1,469 Operating lease right of use assets 102 Goodwill 6,545 Intangible assets — net 2,903 Other assets 324 Non-current assets of discontinued operations 11,343 Liabilities Accounts payable 469 Accrued payroll 209 Accrued income taxes 61 Operating lease liabilities — current 33 Other current liabilities 951 Current liabilities of discontinued operations 1,723 Pension and postretirement benefits 315 Operating lease liabilities 70 Other liabilities 301 Non-current liabilities of discontinued operations 686 Cash flows related to discontinued operations have not been segregated, and are included in the Consolidated Statement of Cash Flows for all periods presented. Selected financial information related to cash flows from discontinued operations is below. Six months ended Selected Cash Flows from Discontinued Operations (millions) 2024 2023 Depreciation and amortization $ 139 $ 277 Purchases of property, plant and equipment (PP&E) 77 104

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregated Revenue	The Company views the following disaggregated disclosures as useful to understanding the composition of revenue recognized during the respective reporting periods: Three months ended Six months ended Net Sales by Division (millions) 2024 2023 2024 2023 Abrasives $ 324 $ 334 $ 652 $ 675 Automotive Aftermarket 304 305 610 617 Electrical Markets 325 329 636 653 Industrial Adhesives and Tapes 531 517 1,049 1,033 Industrial Specialties Division 285 298 569 606 Personal Safety 857 849 1,714 1,717 Roofing Granules 133 133 261 243 Total Safety and Industrial Business Segment 2,759 2,765 5,491 5,544 Advanced Materials 244 305 507 606 Automotive and Aerospace 481 477 987 939 Commercial Branding and Transportation 672 695 1,282 1,310 Electronics 746 714 1,471 1,386 Total Transportation and Electronics Business Segment 2,143 2,191 4,247 4,241 Consumer Safety and Well-Being 280 278 546 548 Home and Auto Care 302 337 607 655 Home Improvement 369 355 699 696 Packaging and Expression 312 323 551 586 Total Consumer Business Segment 1,263 1,293 2,403 2,485 Corporate and Unallocated 86 22 112 45 Other 4 12 18 23 Total Company $ 6,255 $ 6,283 $ 12,271 $ 12,338 Three months ended Six months ended Net Sales by Geographic Area (millions) 2024 2023 2024 2023 Americas $ 3,480 $ 3,396 $ 6,630 $ 6,568 Asia Pacific 1,721 1,776 3,489 3,590 Europe, Middle East and Africa 1,054 1,111 2,152 2,180 Worldwide $ 6,255 $ 6,283 $ 12,271 $ 12,338

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The change in the carrying amount of goodwill by business segment was as follows: (Millions) Safety and Industrial Transportation and Electronics Consumer Corporate and Unallocated Total Company Balance as of December 31, 2023 $ 4,542 $ 1,512 $ 270 $ 58 $ 6,382 Translation and other (42) (10) (12) — (64) Balance as of June 30, 2024 $ 4,500 $ 1,502 $ 258 $ 58 $ 6,318
Schedule of Acquired Intangible Assets	The carrying amount and accumulated amortization of acquired finite-lived intangible assets, in addition to the balance of non-amortizable intangible assets follow: (Millions) June 30, 2024 December 31, 2023 Customer related $ 1,328 $ 1,337 Patents 224 225 Other technology-based 373 375 Definite-lived tradenames 488 489 Other 46 48 Total gross carrying amount 2,459 2,474 Accumulated amortization — customer related (910) (883) Accumulated amortization — patents (223) (224) Accumulated amortization — other technology-based (322) (317) Accumulated amortization — definite-lived tradenames (288) (276) Accumulated amortization — other (30) (31) Total accumulated amortization (1,773) (1,731) Total finite-lived intangible assets — net 686 743 Indefinite lived intangible assets (primarily tradenames) 580 580 Total intangible assets — net $ 1,266 $ 1,323
Schedule of Amortization Expense for Acquired Intangible Assets	Amortization expense follows: Three months ended Six months ended (Millions) 2024 2023 2024 2023 Amortization expense $ 27 $ 29 $ 54 $ 59
Schedule of Expected Amortization Expense for Acquired Amortizable Intangible Assets	Expected amortization expense for acquired amortizable intangible assets recorded as of June 30, 2024 follows: (Millions) Remainder of 2024 2025 2026 2027 2028 2029 After 2029 Amortization expense $ 52 $ 105 $ 104 $ 85 $ 59 $ 57 $ 224

Restructuring Actions (Tables)

Restructuring Actions (Tables)	6 Months Ended
	Jun. 30, 2024
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs	The related restructuring charges for periods presented were recorded in the income (loss) statement as follows: Three months ended Six months ended (Millions) 2024 2023 2024 2023 Cost of sales $ 2 $ 44 $ 4 $ 59 Selling, general and administrative expenses 32 140 123 171 Research, development and related expenses 1 18 11 22 Total operating income impact $ 35 $ 202 $ 138 $ 252 The business segment operating income (loss) impact of these restructuring charges is summarized as follows: Three months ended June 30, 2024 2023 (Millions) Employee Related Asset-Related and Other Total Employee Related Asset-Related and Other Total Safety and Industrial $ 13 $ 5 $ 18 $ 44 $ — $ 44 Transportation and Electronics 7 4 11 25 — 25 Consumer 4 2 6 13 — 13 Corporate and unallocated — — — 100 20 120 Total operating expense $ 24 $ 11 $ 35 $ 182 $ 20 $ 202 Six months ended June 30, 2024 2023 (Millions) Employee Related Asset-Related and Other Total Employee Related Asset-Related and Other Total Safety and Industrial $ 39 $ 25 $ 64 $ 54 $ — $ 54 Transportation and Electronics 16 18 34 37 — 37 Consumer 9 11 20 16 — 16 Corporate and unallocated 6 14 20 125 20 145 Total operating expense $ 70 $ 68 $ 138 $ 232 $ 20 $ 252
Schedule of Restructuring Reserve by Type of Cost	Restructuring actions, including cash and non-cash impacts, follow: (Millions) Employee-Related Asset-Related and Other Total Accrued restructuring action balance as of December 31, 2023 $ 99 $ — $ 99 Incremental expense incurred in the first quarter of 2024 46 57 103 Incremental expense incurred in the second quarter of 2024 24 11 35 Non-cash changes — (68) (68) Adjustments 12 — 12 Cash payments (92) — (92) Accrued restructuring action balance as of June 30, 2024 $ 89 $ — $ 89 (Millions) Employee-Related Accrued restructuring action balance as of December 31, 2023 $ 60 Incremental expense incurred in the first quarter of 2024 4 Incremental expense incurred in the second quarter of 2024 8 Adjustments (4) Cash payments (17) Accrued restructuring action balance as of June 30, 2024 $ 51

Supplemental Income (Loss) St_2

Supplemental Income (Loss) Statement Information (Tables)	6 Months Ended
	Jun. 30, 2024
Other Income and Expenses [Abstract]
Schedule of Other Expense (Income), Net	Other expense (income), net consists of the following: Three months ended Six months ended (Millions) 2024 2023 2024 2023 Interest expense $ 322 $ 144 $ 663 $ 267 Interest income (143) (47) (253) (88) Pension and postretirement net periodic benefit cost (benefit) 796 (25) 785 (51) Solventum ownership - change in value (1,113) — (1,113) — Total $ (138) $ 72 $ 82 $ 128

Supplemental Equity and Compr_2

Supplemental Equity and Comprehensive Income (Loss) Information (Tables)	6 Months Ended
	Jun. 30, 2024
Stockholders' Equity Note [Abstract]
Schedule of Consolidated Statement of Changes in Equity	The table below presents the consolidated changes in equity for three and six months ended June 30, 2024 and 2023: 3M Company Shareholders (Millions) Total Common Stock and Additional Paid-in Capital Retained Earnings Treasury Stock Accumulated Other Comprehensive Income (Loss) Non-controlling Interest Balance at March 31, 2024 $ 4,933 $ 6,982 $ 37,472 $ (32,762) $ (6,826) $ 67 Net income (loss) 1,151 1,145 6 Other comprehensive income (loss), net of tax 674 675 (1) Solventum spin-off (2,169) (2,753) 584 Dividends declared (386) (386) Stock-based compensation 173 173 Reacquired stock (400) (400) Issuances pursuant to stock option and benefit plans 12 (3) 15 Balance at June 30, 2024 $ 3,988 $ 7,155 $ 35,475 $ (33,147) $ (5,567) $ 72 Balance at March 31, 2023 $ 15,351 $ 6,825 $ 47,966 $ (32,963) $ (6,530) $ 53 Net income (6,836) (6,841) 5 Other comprehensive income (loss), net of tax 98 97 1 Dividends declared (828) (828) Stock-based compensation 42 42 Issuances pursuant to stock option and benefit plans 30 (7) 37 Balance at June 30, 2023 $ 7,857 $ 6,867 $ 40,290 $ (32,926) $ (6,433) $ 59 3M Company Shareholders (Millions) Total Common Stock and Additional Paid-in Capital Retained Earnings Treasury Stock Accumulated Other Comprehensive Income (Loss) Non-controlling Interest Balance at December 31, 2023 $ 4,868 $ 6,965 $ 37,479 $ (32,859) $ (6,778) $ 61 Net income (loss) 2,084 2,073 11 Total other comprehensive income (loss), net of tax 627 627 — Solventum spin-off (2,169) (2,753) 584 Dividends declared (1,221) (1,221) Stock-based compensation 190 190 Reacquired stock (421) (421) Issuances pursuant to stock option and benefit plans 30 (103) 133 Balance at June 30, 2024 $ 3,988 $ 7,155 $ 35,475 $ (33,147) $ (5,567) $ 72 Balance at December 31, 2022 $ 14,770 $ 6,700 $ 47,950 $ (33,255) $ (6,673) $ 48 Net income (5,855) (5,865) 10 Total other comprehensive income (loss), net of tax 241 240 1 Dividends declared (1,655) (1,655) Stock-based compensation 167 167 Reacquired stock (29) (29) Issuances pursuant to stock option and benefit plans 218 (140) 358 Balance at June 30, 2023 $ 7,857 $ 6,867 $ 40,290 $ (32,926) $ (6,433) $ 59
Schedule of Changes in Accumulated Other Comprehensive Income (Loss) Attributable to 3M	The table below presents the changes in accumulated other comprehensive income (loss) attributable to 3M (AOCI), including the reclassifications out of AOCI by component for three and six months ended June 30, 2024 and 2023: (Millions) Cumulative Translation Adjustment Defined Benefit Pension and Postretirement Plans Adjustment Cash Flow Hedging Instruments, Unrealized Gain (Loss) Total Accumulated Other Comprehensive Income (Loss) Balance at March 31, 2024, net of tax: $ (2,715) $ (4,083) $ (28) $ (6,826) Other comprehensive income (loss), before tax: Amounts before reclassifications (148) 218 23 93 Amounts reclassified out 11 876 (30) 857 Total other comprehensive income (loss), before tax (137) 1,094 (7) 950 Tax effect 2 (7) (268) — (275) Total other comprehensive income (loss), net of tax (144) 826 (7) 675 Solventum spin-off 64 520 — 584 Balance at June 30, 2024, net of tax: $ (2,795) $ (2,737) $ (35) $ (5,567) Balance at March 31, 2023, net of tax: $ (2,712) $ (3,787) $ (31) $ (6,530) Other comprehensive income (loss), before tax: Amounts before reclassifications 3 — 72 75 Amounts reclassified out 39 65 (40) 64 Total other comprehensive income (loss), before tax 42 65 32 139 Tax effect 2 (18) (15) (9) (42) Total other comprehensive income (loss), net of tax 24 50 23 97 Balance at June 30, 2023, net of tax: $ (2,688) $ (3,737) $ (8) $ (6,433) (Millions) Cumulative Translation Adjustment Defined Benefit Pension and Postretirement Plans Adjustment Cash Flow Hedging Instruments, Unrealized Gain (Loss) Total Accumulated Other Comprehensive Income (Loss) Balance at December 31, 2023, net of tax: $ (2,506) $ (4,218) $ (54) $ (6,778) Other comprehensive income (loss), before tax: Amounts before reclassifications (401) 285 84 (32) Amounts reclassified out 68 972 (57) 983 Total other comprehensive income (loss), before tax (333) 1,257 27 951 Tax effect 2 (20) (296) (8) (324) Total other comprehensive income (loss), net of tax (353) 961 19 627 Solventum spin-off 64 520 — 584 Balance at June 30, 2024, net of tax: $ (2,795) $ (2,737) $ (35) $ (5,567) Balance at December 31, 2022, net of tax: $ (2,828) $ (3,838) $ (7) $ (6,673) Other comprehensive income (loss), before tax: Amounts before reclassifications 108 — 78 186 Amounts reclassified out 39 129 (81) 87 Total other comprehensive income (loss), before tax 147 129 (3) 273 Tax effect 2 (7) (28) 2 (33) Total other comprehensive income (loss), net of tax 140 101 (1) 240 Balance at June 30, 2023, net of tax: $ (2,688) $ (3,737) $ (8) $ (6,433) Includes tax expense (benefit) reclassified out of AOCI related to the following: Three months ended June 30, Six months ended June 30, (millions) 2024 2023 2024 2023 Cumulative Translation Adjustment $ — $ — $ — $ — Defined benefit pension and postretirement plans adjustment (216) (15) (229) (28) Cash flow hedging instruments, unrealized gain/loss 7 8 13 18

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Schedule of Earnings (Loss) Per Share Computations	The computations for basic and diluted earnings (loss) per share follow: Three months ended Six months ended (Amounts in millions, except per share amounts) 2024 2023 2024 2023 Numerator: Net income (loss) from continuing operations attributable to 3M $ 1,204 $ (7,171) $ 1,909 $ (6,509) Net income (loss) from discontinued operations, net of taxes (59) 330 164 644 Net income (loss) attributable to 3M $ 1,145 $ (6,841) $ 2,073 $ (5,865) Denominator: Denominator for weighted average 3M common shares outstanding – basic 553.8 553.9 554.4 553.3 Dilution associated with stock-based compensation plans 1.0 — 0.9 — Denominator for weighted average 3M common shares outstanding – diluted 554.8 553.9 555.3 553.3 Earnings (loss) per share attributable to 3M common shareholders: Earnings (loss) per share from continuing operations — basic $ 2.17 $ (12.94) $ 3.44 $ (11.76) Earnings (loss) per share from discontinued operations — basic (0.10) 0.59 0.30 1.16 Earnings (loss) per share — basic $ 2.07 $ (12.35) $ 3.74 $ (10.60) Earnings (loss) per share from continuing operations — diluted $ 2.17 $ (12.94) $ 3.44 $ (11.76) Earnings (loss) per share from discontinued operations — diluted (0.10) 0.59 0.29 1.16 Earnings (loss) per share — diluted $ 2.07 $ (12.35) $ 3.73 $ (10.60)

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2024
Debt Securities, Available-for-Sale [Abstract]
Schedule of Marketable Securities	The following is a summary of amounts recorded on the Consolidated Balance Sheet for marketable securities (current and non-current). (Millions) June 30, 2024 December 31, 2023 Asset backed securities $ 4 $ — Foreign corporate debt 6 — U.S. government securities 27 — Corporate debt securities 70 — Commercial paper 40 — Certificates of deposit/time deposits 91 46 U.S. treasury securities 13 — U.S. municipal securities 4 4 Current marketable securities 255 50 Asset backed securities 4 — Corporate debt securities 10 — U.S. municipal securities 20 20 Non-current marketable securities 34 20 Total marketable securities $ 289 $ 70
Schedule of Marketable Securities by Contractual Maturity	The balances at June 30, 2024 for marketable securities by contractual maturity are shown below. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (Millions) Due in one year or less $ 255 Due after one year through five years 25 Due after five years through ten years 9 Total marketable securities $ 289

Long-Term Debt and Short-Term_2

Long-Term Debt and Short-Term Borrowings (Tables)	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Schedule of Maturities of Long-Term Debt	The maturities of long-term debt for the periods subsequent to June 30, 2024 are as follows (in millions): Remainder of 2024 2025 2026 2027 2028 2029 After 2029 Total $ 53 $ 1,868 $ 1,540 $ 847 $ 818 $ 1,790 $ 6,167 $ 13,083

Pension and Postretirement Be_2

Pension and Postretirement Benefit Plans (Tables)	6 Months Ended
	Jun. 30, 2024
Retirement Benefits [Abstract]
Schedule of Net Periodic Benefit Cost (Benefit)	The other components of net periodic benefit cost are reflected in other expense (income), net. Effective April 1, 2024, approximately $2.7 billion of benefit obligations and $2.4 billion of plan assets for certain pension and postretirement benefit plans, were transferred to Solventum, which is treated as a discontinued operation. Components of net periodic benefit cost and other supplemental information for the three and six months ended June 30, 2024 and 2023 follow: Three months ended June 30, Qualified and Non-qualified Pension Benefits Postretirement Benefits United States International (Millions) 2024 2023 2024 2023 2024 2023 Net periodic benefit cost (benefit) Operating expense Service cost $ 29 $ 43 $ 14 $ 20 $ 5 $ 6 Non-operating expense Interest cost 141 165 49 54 21 23 Expected return on plan assets (196) (244) (80) (75) (15) (19) Amortization of transition asset — — 1 1 — — Amortization of prior service benefit (4) (6) — — (6) (8) Amortization of net actuarial loss 83 74 3 2 4 2 Settlements, curtailments, special termination benefits and other 795 — — — — — Total non-operating expense (benefit) 819 (11) (27) (18) 4 (2) Total net periodic benefit cost (benefit) 848 32 (13) 2 9 4 Service cost - continuing operations $ 29 $ 35 $ 14 $ 16 $ 5 $ 5 Service cost - discontinued operations — 8 — 4 — 1 Total service cost 29 43 14 20 5 6 Non-operating expense (benefit) - continuing operations 819 (7) (27) (16) 4 (2) Non-operating expense (benefit) - discontinued operations — (4) — (2) — — Total non-operating expense (benefit) 819 (11) (27) (18) 4 (2) Total net periodic benefit cost (benefit) - continuing operations 848 28 (13) — 9 3 Total net periodic benefit cost (benefit) - discontinued operations — 4 — 2 — 1 Total net periodic benefit cost (benefit) $ 848 $ 32 $ (13) $ 2 $ 9 $ 4 Six months ended June 30, Qualified and Non-qualified Pension Benefits Postretirement Benefits United States International (Millions) 2024 2023 2024 2023 2024 2023 Net periodic benefit cost (benefit) Operating expense Service cost $ 66 $ 86 $ 35 $ 39 $ 12 $ 12 Non-operating expense Interest cost 301 331 103 109 43 45 Expected return on plan assets (433) (488) (167) (150) (34) (38) Amortization of transition asset — — 2 1 — — Amortization of prior service benefit (8) (12) 1 1 (12) (16) Amortization of net actuarial loss 178 147 6 4 10 4 Settlements, curtailments, special termination benefits and other 795 — — — — — Total non-operating expense (benefit) 833 (22) (55) (35) 7 (5) Total net periodic benefit cost (benefit) 899 64 (20) 4 19 7 Service cost - continuing operations $ 59 $ 70 $ 30 $ 31 $ 11 $ 10 Service cost - discontinued operations 7 16 5 8 1 2 Total service cost 66 86 35 39 12 12 Non-operating expense (benefit) - continuing operations 833 (14) (55) (33) 7 (4) Non-operating expense (benefit) - discontinued operations — (8) — (2) — (1) Total non-operating expense (benefit) 833 (22) (55) (35) 7 (5) Total net periodic benefit cost (benefit) - continuing operations 892 56 (25) (2) 18 6 Total net periodic benefit cost (benefit) - discontinued operations 7 8 5 6 1 1 Total net periodic benefit cost (benefit) $ 899 $ 64 $ (20) $ 4 $ 19 $ 7

Derivatives (Tables)

Derivatives (Tables)	6 Months Ended
	Jun. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Gains (Loss) on Derivative Instruments Designated as Hedges	The amount of pretax gain (loss) recognized in other comprehensive income (loss) related to derivative instruments designated as cash flow hedges is provided in the following table. Pretax Gain (Loss) Recognized in Other Comprehensive Income (Loss) on Derivative Three months ended Six months ended (Millions) 2024 2023 2024 2023 Foreign currency forward/option contracts $ 23 $ 72 $ 84 $ 78
Schedule of Gain (loss) on Derivative Instruments Designated as Fair Value Hedges	The following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustments for active fair value hedges, as well as remaining amounts for discontinued fair value hedges: Location on the Consolidated Balance Sheet (Millions) Carrying Value of the Hedged Liabilities Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Value of the Hedged Liabilities June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 Long-term debt $ 909 $ 918 $ (93) $ (84)
Schedule of Gain (Loss) on Derivative and Non-Derivative Instruments Designated as Net Investment Hedges	The amount of pre-tax gain (loss) recognized in other comprehensive income (loss) related to derivative and nonderivative instruments designated as net investment hedges are as follows. Pretax Gain (Loss) Recognized as Cumulative Translation within Other Comprehensive Income (Loss) Three months ended Six months ended (Millions) 2024 2023 2024 2023 Foreign currency denominated debt $ 13 $ (22) $ 56 $ (65) Foreign currency forward contracts 2 (1) 5 (3) Total $ 15 $ (23) $ 61 $ (68)
Schedule of Location in Consolidated Statement of Income and Pre-Tax Amounts Recognized in Income Related to Derivative Instruments Designated in Cash Flow or Fair Value Hedging Relationship	Three months ended June 30, Six months ended June 30, Cost of sales Other expense (income), net Cost of sales Other expense (income), net (Millions) 2024 2023 2024 2023 2024 2023 2024 2023 Total consolidated financial statement line item amount $ 3,571 $ 3,728 $ (138) $ 72 $ 7,056 $ 7,472 $ 82 $ 128 Pre-tax amounts recognized in income related to derivative instruments Information regarding cash flow and fair value hedging relationships: (Gain) or loss on cash flow hedging relationships: Foreign currency forward/option contracts: Amount of (gain) or loss reclassified from accumulated other comprehensive income (loss) into income * (32) (42) — — (61) (85) — — Interest rate contracts: Amount of (gain) or loss reclassified from accumulated other comprehensive income (loss) into income — — 2 2 — — 4 4 (Gain) or loss on fair value hedging relationships: Interest rate contracts: Hedged items — — 2 (9) — — (9) 3 Derivatives designated as hedging instruments — — (2) 9 — — 9 (3) Information regarding derivatives not designated as hedging instruments: (Gain) or loss on derivatives not designated as instruments: Foreign currency forward/option contracts 2 13 4 (39) 7 5 6 (13) * For periods prior to the April 1, 2024 separation of Solventum, these include certain insignificant amounts attributable to discontinued operations.
Schedule of Location and Fair Value of Derivative Instruments	The following tables summarize the fair value of 3M’s derivative instruments, excluding nonderivative instruments used as hedging instruments, and their location in the consolidated balance sheet. Notional amounts below are presented at period end foreign exchange rates, except for certain interest rate swaps, which are presented using the inception date’s foreign exchange rate. Gross Notional Amount Assets Liabilities (Millions) Location Fair Value Amount Location Fair Value Amount June 30, December 31, June 30, December 31, June 30, December 31, Derivatives designated as hedging instruments Foreign currency forward/option contracts $ 1,821 $ 2,109 Other current assets $ 74 $ 68 Other current liabilities $ 5 $ 27 Foreign currency forward/option contracts 725 342 Other assets 12 11 Other liabilities 5 5 Interest rate contracts 800 800 Other assets — — Other liabilities 96 88 Total derivatives designated as hedging instruments 86 79 106 120 Derivatives not designated as hedging instruments Foreign currency forward/option contracts 659 1,023 Other current assets — 5 Other current liabilities 1 7 Total derivatives not designated as hedging instruments — 5 1 7 Total derivative instruments $ 86 $ 84 $ 107 $ 127

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table provide information by level for material assets and liabilities that are measured at fair value on a recurring basis at June 30, 2024 and December 31, 2023. Fair Value at Fair Value Measurements Using Inputs Considered as Level 1 Level 2 Level 3 Description (Millions) June 30, December 31, June 30, December 31, June 30, December 31, June 30, December 31, Assets: Available-for-sale: Marketable securities: Asset backed securities $ 8 $ — $ — $ — $ 8 $ — $ — $ — Foreign corporate debt 6 — — — 6 — — — U.S. government securities 27 — 27 — — — — — Corporate debt securities 80 — — — 80 — — — Commercial paper 40 — — — 40 — — — Certificates of deposit/time deposits 91 46 — — 91 46 — — U.S. treasury securities 13 — 13 — — — — — U.S. municipal securities 24 24 — — — — 24 24 Solventum common stock 1,817 — 1,817 — — — — — Derivative instruments — assets: Foreign currency forward/option contracts 86 84 — — 86 84 — — Liabilities: Derivative instruments — liabilities: Foreign currency forward/option contracts 11 39 — — 11 39 — — Interest rate contracts 96 88 — — 96 88 — —
Schedule of Fair Value, by Balance Sheet Grouping	Information with respect to the carrying amounts and estimated fair values of these financial instruments follow: June 30, 2024 December 31, 2023 (Millions) Carrying Value Fair Value Carrying Value Fair Value Long-term debt, excluding current portion $ 11,781 $ 10,374 $ 13,088 $ 11,859

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-Based Compensation Expense	Amounts recognized in the financial statements with respect to stock-based compensation programs, which include stock options, restricted stock, restricted stock units, performance shares and the General Employees’ Stock Purchase Plan (GESPP), are provided in the following table. Capitalized stock-based compensation amounts were not material. Three months ended Six months ended (Millions) 2024 2023 2024 2023 Cost of sales $ 19 $ 8 $ 24 $ 26 Selling, general and administrative expenses 107 21 125 100 Research, development and related expenses 28 6 31 29 Stock-based compensation expenses 154 35 180 155 Income tax benefits (33) (4) (14) (28) Stock-based compensation expenses (benefits), net of tax $ 121 $ 31 $ 166 $ 127

Business Segments (Tables)

Business Segments (Tables)	6 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
Schedule of Business Segment Information	Business Segment Information Three months ended Six months ended Net Sales (Millions) 2024 2023 2024 2023 Safety and Industrial $ 2,759 $ 2,765 $ 5,491 $ 5,544 Transportation and Electronics 2,143 2,191 4,247 4,241 Consumer 1,263 1,293 2,403 2,485 Corporate and Unallocated 86 22 112 45 Other 4 12 18 23 Total Company $ 6,255 $ 6,283 $ 12,271 $ 12,338 Operating Performance (Millions) - income (loss) Safety and Industrial $ 612 $ 534 $ 1,269 $ 1,135 Transportation and Electronics 428 410 909 704 Consumer 219 235 435 414 Corporate and Unallocated Corporate special items: Net costs for significant litigation (8) (10,357) (71) (10,439) Divestiture costs (14) (1) (20) (4) Russia exit (charges) benefits — 18 — 18 Total corporate special items (22) (10,340) (91) (10,425) Other corporate (expense) income - net (2) (207) (73) (339) Total Corporate and Unallocated (24) (10,547) (164) (10,764) Other 37 10 (28) 19 Total Company operating income (loss) 1,272 (9,358) 2,421 (8,492) Other expense/(income), net (138) 72 82 128 Income (loss) before income taxes $ 1,410 $ (9,430) $ 2,339 $ (8,620)

Significant Accounting Polici_3

Significant Accounting Policies (Details)	Apr. 01, 2024
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff | Health Care Segment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Ownership interest of outstanding shares ( as a percent)	80.10%

Discontinued Operations - Narra

Discontinued Operations - Narrative (Details) - USD ($) $ in Millions		3 Months Ended
	Apr. 01, 2024	Jun. 30, 2024
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Transition service and distribution Agreement term	2 years
Manufacturing agreement term	3 years
Intial term	3 years
Gross fees, net of assigned costs		$ 200
Minimum
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Extension for particular products	10 years
Maximum
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Extension for particular products	12 years
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Other income		30
Amounts due from solventum		500
Amounts due to solventum		$ 200
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff | Health Care Segment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Ownership interest of outstanding shares ( as a percent)	80.10%

Discontinued Operations - Incom

Discontinued Operations - Income (Loss) from Discontinued Operations (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cost of sales	$ 0	$ 878	$ 844	$ 1,747
Other operating expenses	46	764	837	1,496
Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net sales	0	2,042	1,987	4,018
Other expense (income), net	0	(7)	44	(11)
Income (loss) from discontinued operations before income taxes	(46)	407	262	786
Provision for income taxes	13	77	98	142
Net income (loss) from discontinued operations, net of taxes	$ (59)	$ 330	$ 164	$ 644

Discontinued Operations - Asset

Discontinued Operations - Assets and Liabilities of Discontinued Operations (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Assets
Marketable securities — current	$ 255	$ 50
Non-current assets of discontinued operations	0	11,343
Liabilities
Current liabilities of discontinued operations	0	1,723
Non-current liabilities of discontinued operations	$ 0	686
Discontinued Operations, Disposed of by Sale
Assets
Cash and cash equivalents		198
Marketable securities — current		3
Accounts receivable — net		1,149
Inventories		878
Other current assets		151
Current assets of discontinued operations		2,379
Property, plant and equipment — net		1,469
Operating lease right of use assets		102
Goodwill		6,545
Intangible assets — net		2,903
Other assets		324
Non-current assets of discontinued operations		11,343
Liabilities
Accounts payable		469
Accrued payroll		209
Accrued income taxes		61
Operating lease liabilities — current		33
Other current liabilities		951
Current liabilities of discontinued operations		1,723
Pension and postretirement benefits		315
Operating lease liabilities		70
Other liabilities		301
Non-current liabilities of discontinued operations		$ 686

Discontinued Operations - Cash

Discontinued Operations - Cash Flows from Discontinued Operations (Details) - Discontinued Operations, Disposed of by Sale - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation and amortization	$ 139	$ 277
Purchases of property, plant and equipment (PP&E)	$ 77	$ 104

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disaggregation of Revenue [Line Items]
Net sales	$ 6,255	$ 6,283	$ 12,271	$ 12,338
United States
Disaggregation of Revenue [Line Items]
Net sales	2,800	2,800	5,300	5,300
China/Hong Kong
Disaggregation of Revenue [Line Items]
Net sales	$ 700	$ 600	$ 1,400	$ 1,300

Revenue - Disaggregated Revenue

Revenue - Disaggregated Revenue (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disaggregation of Revenue [Line Items]
Net sales	$ 6,255	$ 6,283	$ 12,271	$ 12,338
Corporate and Unallocated
Disaggregation of Revenue [Line Items]
Net sales	86	22	112	45
Other
Disaggregation of Revenue [Line Items]
Net sales	4	12	18	23
Americas
Disaggregation of Revenue [Line Items]
Net sales	3,480	3,396	6,630	6,568
Asia Pacific
Disaggregation of Revenue [Line Items]
Net sales	1,721	1,776	3,489	3,590
Europe, Middle East and Africa
Disaggregation of Revenue [Line Items]
Net sales	1,054	1,111	2,152	2,180
Safety and Industrial | Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	2,759	2,765	5,491	5,544
Safety and Industrial | Abrasives | Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	324	334	652	675
Safety and Industrial | Automotive Aftermarket | Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	304	305	610	617
Safety and Industrial | Electrical Markets | Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	325	329	636	653
Safety and Industrial | Industrial Adhesives and Tapes | Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	531	517	1,049	1,033
Safety and Industrial | Industrial Specialties Division | Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	285	298	569	606
Safety and Industrial | Personal Safety | Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	857	849	1,714	1,717
Safety and Industrial | Roofing Granules | Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	133	133	261	243
Transportation and Electronics | Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	2,143	2,191	4,247	4,241
Transportation and Electronics | Advanced Materials | Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	244	305	507	606
Transportation and Electronics | Automotive and Aerospace | Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	481	477	987	939
Transportation and Electronics | Commercial Branding and Transportation | Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	672	695	1,282	1,310
Transportation and Electronics | Electronics | Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	746	714	1,471	1,386
Consumer | Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	1,263	1,293	2,403	2,485
Consumer | Consumer Safety and Well-Being | Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	280	278	546	548
Consumer | Home and Auto Care | Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	302	337	607	655
Consumer | Home Improvement | Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	369	355	699	696
Consumer | Packaging and Expression | Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	$ 312	$ 323	$ 551	$ 586

Divestitures (Details)

Divestitures (Details)	Apr. 01, 2024
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff | Health Care Segment
Business Acquisition [Line Items]
Ownership interest of outstanding shares ( as a percent)	80.10%

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill Balance by Business Segment (Details) $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($)
Goodwill
Balance at the beginning of the period	$ 6,382
Translation and other	(64)
Balance at the end of the period	6,318
Goodwill, accumulated impairment loss	300
Corporate and Unallocated
Goodwill
Balance at the beginning of the period	58
Translation and other	0
Balance at the end of the period	58
Safety and Industrial | Operating Segments
Goodwill
Balance at the beginning of the period	4,542
Translation and other	(42)
Balance at the end of the period	4,500
Transportation and Electronics | Operating Segments
Goodwill
Balance at the beginning of the period	1,512
Translation and other	(10)
Balance at the end of the period	1,502
Consumer | Operating Segments
Goodwill
Balance at the beginning of the period	270
Translation and other	(12)
Balance at the end of the period	$ 258

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Acquired Intangible Assets (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Acquired intangible assets disclosures
Total gross carrying amount	$ 2,459	$ 2,474
Total accumulated amortization	(1,773)	(1,731)
Total finite-lived intangible assets — net	686	743
Indefinite lived intangible assets (primarily tradenames)	580	580
Total intangible assets — net	1,266	1,323
Customer related
Acquired intangible assets disclosures
Total gross carrying amount	1,328	1,337
Total accumulated amortization	(910)	(883)
Patents
Acquired intangible assets disclosures
Total gross carrying amount	224	225
Total accumulated amortization	(223)	(224)
Other technology-based
Acquired intangible assets disclosures
Total gross carrying amount	373	375
Total accumulated amortization	(322)	(317)
Definite-lived tradenames
Acquired intangible assets disclosures
Total gross carrying amount	488	489
Total accumulated amortization	(288)	(276)
Other
Acquired intangible assets disclosures
Total gross carrying amount	46	48
Total accumulated amortization	$ (30)	$ (31)

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Narrative (Details)	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Tradenames not amortized, period of existence	60 years

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Amortization Expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 27	$ 29	$ 54	$ 59
Expected amortization expense for acquired intangible assets recorded as of balance sheet date
Remainder of 2024	52		52
2025	105		105
2026	104		104
2027	85		85
2028	59		59
2029	57		57
After 2029	$ 224		$ 224

Restructuring Actions - Narrati

Restructuring Actions - Narrative (Details) $ in Millions	3 Months Ended			6 Months Ended		12 Months Ended	18 Months Ended
	Jun. 30, 2024 USD ($) position	Mar. 31, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) position	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Jun. 30, 2024 USD ($) position
2023 to 2025 Restructuring Actions
Restructuring Cost and Reserve
Restructuring and related cost, expected number of positions affected | position				8,000
2023 to 2025 Restructuring Actions | Minimum | Employee Related
Restructuring Cost and Reserve
Expected charges	$ 700			$ 700			$ 700
2023 to 2025 Restructuring Actions | Maximum | Employee Related
Restructuring Cost and Reserve
Expected charges	800			$ 800			$ 800
2023 Restructuring Actions
Restructuring Cost and Reserve
Restructuring and related cost, expected number of positions affected | position				700			6,400
Restructuring charges	35	$ 103	$ 202	$ 138	$ 252	$ 415
2023 Restructuring Actions | Employee Related
Restructuring Cost and Reserve
Restructuring charges	$ 24	46	$ 182	$ 70	$ 232
2023 to 2025 PFAS Exit Actions
Restructuring Cost and Reserve
Restructuring and related cost, expected number of positions affected | position	610			60
Restructuring charges	$ 8			$ 12		$ 64
2023 to 2025 PFAS Exit Actions | Employee Related
Restructuring Cost and Reserve
Restructuring charges	$ 8	$ 4

Restructuring Actions - Restruc

Restructuring Actions - Restructuring Charges (Details) - 2023 Restructuring Actions - USD ($) $ in Millions	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Restructuring Cost and Reserve
Restructuring charges	$ 35	$ 103	$ 202	$ 138	$ 252	$ 415
Cost of sales
Restructuring Cost and Reserve
Restructuring charges	2		44	4	59
Selling, general and administrative expenses
Restructuring Cost and Reserve
Restructuring charges	32		140	123	171
Research, development and related expenses
Restructuring Cost and Reserve
Restructuring charges	$ 1		$ 18	$ 11	$ 22

Restructuring Actions - Impact

Restructuring Actions - Impact of Restructuring Charges (Details) - 2023 Restructuring Actions - USD ($) $ in Millions	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Restructuring Cost and Reserve
Restructuring charges	$ 35	$ 103	$ 202	$ 138	$ 252	$ 415
Employee Related
Restructuring Cost and Reserve
Restructuring charges	24	46	182	70	232
Asset-Related and Other
Restructuring Cost and Reserve
Restructuring charges	11	$ 57	20	68	20
Operating Segments | Safety and Industrial
Restructuring Cost and Reserve
Restructuring charges	18		44	64	54
Operating Segments | Transportation and Electronics
Restructuring Cost and Reserve
Restructuring charges	11		25	34	37
Operating Segments | Consumer
Restructuring Cost and Reserve
Restructuring charges	6		13	20	16
Operating Segments | Employee Related | Safety and Industrial
Restructuring Cost and Reserve
Restructuring charges	13		44	39	54
Operating Segments | Employee Related | Transportation and Electronics
Restructuring Cost and Reserve
Restructuring charges	7		25	16	37
Operating Segments | Employee Related | Consumer
Restructuring Cost and Reserve
Restructuring charges	4		13	9	16
Operating Segments | Asset-Related and Other | Safety and Industrial
Restructuring Cost and Reserve
Restructuring charges	5		0	25	0
Operating Segments | Asset-Related and Other | Transportation and Electronics
Restructuring Cost and Reserve
Restructuring charges	4		0	18	0
Operating Segments | Asset-Related and Other | Consumer
Restructuring Cost and Reserve
Restructuring charges	2		0	11	0
Corporate and Unallocated
Restructuring Cost and Reserve
Restructuring charges	0		120	20	145
Corporate and Unallocated | Employee Related
Restructuring Cost and Reserve
Restructuring charges	0		100	6	125
Corporate and Unallocated | Asset-Related and Other
Restructuring Cost and Reserve
Restructuring charges	$ 0		$ 20	$ 14	$ 20

Restructuring Actions - Cash an

Restructuring Actions - Cash and Non-Cash Impacts (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
2023 Restructuring Actions
Restructuring Reserve Roll Forward
Accrued restructuring action balances, beginning balance		$ 99		$ 99
Restructuring charges	$ 35	103	$ 202	138	$ 252	$ 415
Non-cash changes				(68)
Adjustments				12
Cash payments				(92)
Accrued restructuring actions balances, ending balance	89			89		99
2023 to 2025 PFAS Exit Actions
Restructuring Reserve Roll Forward
Restructuring charges	8			12		64
Employee Related | 2023 Restructuring Actions
Restructuring Reserve Roll Forward
Accrued restructuring action balances, beginning balance		99		99
Restructuring charges	24	46	182	70	232
Non-cash changes				0
Adjustments				12
Cash payments				(92)
Accrued restructuring actions balances, ending balance	89			89		99
Employee Related | 2023 to 2025 PFAS Exit Actions
Restructuring Reserve Roll Forward
Accrued restructuring action balances, beginning balance		60		60
Restructuring charges	8	4
Adjustments				(4)
Cash payments				(17)
Accrued restructuring actions balances, ending balance	51			51		60
Asset-Related and Other | 2023 Restructuring Actions
Restructuring Reserve Roll Forward
Accrued restructuring action balances, beginning balance		0		0
Restructuring charges	11	$ 57	$ 20	68	$ 20
Non-cash changes				(68)
Adjustments				0
Cash payments				0
Accrued restructuring actions balances, ending balance	$ 0			$ 0		$ 0

Supplemental Income (Loss) St_3

Supplemental Income (Loss) Statement Information - Other Expense (Income), Net (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Other Income and Expenses [Abstract]
Interest expense	$ 322	$ 144	$ 663	$ 267
Interest income	(143)	(47)	(253)	(88)
Pension and postretirement net periodic benefit cost (benefit)	796	(25)	785	(51)
Solventum ownership - change in value	(1,113)	0	(1,113)	0
Other expense (income), net	$ (138)	$ 72	$ 82	$ 128

Supplemental Income (Loss) St_4

Supplemental Income (Loss) Statement Information - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024
Other Income and Expenses [Abstract]
Settlements, curtailments, special termination benefits and other	$ 795
Unrealized gain on investments		$ 1,100

Supplemental Equity and Compr_3

Supplemental Equity and Comprehensive Income (Loss) Information - Narrative (Details) - $ / shares	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Stockholders' Equity Note [Abstract]
Dividends declared in period (in dollars per share)	$ 0.70	$ 1.51	$ 1.50	$ 1.50	$ 2.21	$ 3

Supplemental Equity and Compr_4

Supplemental Equity and Comprehensive Income (Loss) Information - Changes in Equity (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024		Jun. 30, 2023
Increase (decrease) in equity
Balance at the beginning of the period	$ 4,933	$ 15,351	$ 4,868		$ 14,770
Net income (loss)	1,151	(6,836)	2,084	[1]	(5,855)	[1]
Other comprehensive income (loss), net of tax:
Other comprehensive income (loss), net of tax	674	98	627		241
Solventum spin-off	(2,169)		(2,169)
Dividends declared	(386)	(828)	(1,221)		(1,655)
Stock-based compensation	173	42	190		167
Reacquired stock	(400)		(421)		(29)
Issuances pursuant to stock option and benefit plans	12	30	30		218
Balance at the end of the period	3,988	7,857	3,988		7,857
Common Stock and Additional Paid-in Capital
Increase (decrease) in equity
Balance at the beginning of the period	6,982	6,825	6,965		6,700
Other comprehensive income (loss), net of tax:
Stock-based compensation	173	42	190		167
Balance at the end of the period	7,155	6,867	7,155		6,867
Retained Earnings
Increase (decrease) in equity
Balance at the beginning of the period	37,472	47,966	37,479		47,950
Net income (loss)	1,145	(6,841)	2,073		(5,865)
Other comprehensive income (loss), net of tax:
Solventum spin-off	(2,753)		(2,753)
Dividends declared	(386)	(828)	(1,221)		(1,655)
Issuances pursuant to stock option and benefit plans	(3)	(7)	(103)		(140)
Balance at the end of the period	35,475	40,290	35,475		40,290
Treasury Stock
Increase (decrease) in equity
Balance at the beginning of the period	(32,762)	(32,963)	(32,859)		(33,255)
Other comprehensive income (loss), net of tax:
Reacquired stock	(400)		(421)		(29)
Issuances pursuant to stock option and benefit plans	15	37	133		358
Balance at the end of the period	(33,147)	(32,926)	(33,147)		(32,926)
Accumulated Other Comprehensive Income (Loss)
Increase (decrease) in equity
Balance at the beginning of the period	(6,826)	(6,530)	(6,778)		(6,673)
Other comprehensive income (loss), net of tax:
Other comprehensive income (loss), net of tax	675	97	627		240
Solventum spin-off	584		584
Balance at the end of the period	(5,567)	(6,433)	(5,567)		(6,433)
Non-controlling Interest
Increase (decrease) in equity
Balance at the beginning of the period	67	53	61		48
Net income (loss)	6	5	11		10
Other comprehensive income (loss), net of tax:
Other comprehensive income (loss), net of tax	(1)	1			1
Balance at the end of the period	$ 72	$ 59	$ 72		$ 59
[1] The Consolidated Statements of Cash Flows include the results of continuing and discontinued operations and, therefore, also include cash and cash equivalents associated with Solventum through its April 2024 separation from 3M that were presented in current assets of discontinued operations in the 3M Consolidated Balance Sheet.

Supplemental Equity and Compr_5

Supplemental Equity and Comprehensive Income (Loss) Information - AOCI Rollforward (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
AOCI Attributable to 3M, Net of Tax Roll Forward
Balance at the beginning of the period	$ 4,933	$ 15,351	$ 4,868	$ 14,770
Other comprehensive income (loss), before tax:
Total other comprehensive income (loss), net of tax	674	98	627	241
Solventum spin-off	(2,169)		(2,169)
Balance at the end of the period	3,988	7,857	3,988	7,857
Total Accumulated Other Comprehensive Income (Loss)
AOCI Attributable to 3M, Net of Tax Roll Forward
Balance at the beginning of the period	(6,826)	(6,530)	(6,778)	(6,673)
Other comprehensive income (loss), before tax:
Amounts before reclassifications	93	75	(32)	186
Amounts reclassified out	857	64	983	87
Total other comprehensive income (loss), before tax	950	139	951	273
Tax effect	(275)	(42)	(324)	(33)
Total other comprehensive income (loss), net of tax	675	97	627	240
Solventum spin-off	584		584
Balance at the end of the period	(5,567)	(6,433)	(5,567)	(6,433)
Cumulative Translation Adjustment
AOCI Attributable to 3M, Net of Tax Roll Forward
Balance at the beginning of the period	(2,715)	(2,712)	(2,506)	(2,828)
Other comprehensive income (loss), before tax:
Amounts before reclassifications	(148)	3	(401)	108
Amounts reclassified out	11	39	68	39
Total other comprehensive income (loss), before tax	(137)	42	(333)	147
Tax effect	(7)	(18)	(20)	(7)
Total other comprehensive income (loss), net of tax	(144)	24	(353)	140
Solventum spin-off	64		64
Balance at the end of the period	(2,795)	(2,688)	(2,795)	(2,688)
Defined Benefit Pension and Postretirement Plans Adjustment
AOCI Attributable to 3M, Net of Tax Roll Forward
Balance at the beginning of the period	(4,083)	(3,787)	(4,218)	(3,838)
Other comprehensive income (loss), before tax:
Amounts before reclassifications	218	0	285	0
Amounts reclassified out	876	65	972	129
Total other comprehensive income (loss), before tax	1,094	65	1,257	129
Tax effect	(268)	(15)	(296)	(28)
Total other comprehensive income (loss), net of tax	826	50	961	101
Solventum spin-off	520		520
Balance at the end of the period	(2,737)	(3,737)	(2,737)	(3,737)
Cash Flow Hedging Instruments, Unrealized Gain (Loss)
AOCI Attributable to 3M, Net of Tax Roll Forward
Balance at the beginning of the period	(28)	(31)	(54)	(7)
Other comprehensive income (loss), before tax:
Amounts before reclassifications	23	72	84	78
Amounts reclassified out	(30)	(40)	(57)	(81)
Total other comprehensive income (loss), before tax	(7)	32	27	(3)
Tax effect	0	(9)	(8)	2
Total other comprehensive income (loss), net of tax	(7)	23	19	(1)
Solventum spin-off	0		0
Balance at the end of the period	$ (35)	$ (8)	$ (35)	$ (8)

Supplemental Equity and Compr_6

Supplemental Equity and Comprehensive Income (Loss) Information - Reclassifications Out of AOCI (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Amount Reclassified from Accumulated Other Comprehensive Income
Provision (benefit) for income taxes	$ 203	$ (2,261)	$ 423	$ (2,116)
Reclassification out of Accumulated Other Comprehensive Income (Loss) | Cumulative Translation Adjustment
Amount Reclassified from Accumulated Other Comprehensive Income
Provision (benefit) for income taxes	0	0	0	0
Reclassification out of Accumulated Other Comprehensive Income (Loss) | Defined Benefit Pension and Postretirement Plans Adjustment
Amount Reclassified from Accumulated Other Comprehensive Income
Provision (benefit) for income taxes	(216)	(15)	(229)	(28)
Reclassification out of Accumulated Other Comprehensive Income (Loss) | Cash Flow Hedging Instruments, Unrealized Gain (Loss)
Amount Reclassified from Accumulated Other Comprehensive Income
Provision (benefit) for income taxes	$ 7	$ 8	$ 13	$ 18

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Tax Credit Carryforward [Line Items]
Effective tax rate (as a percent)	14.40%	24%	18.10%	24.60%
Unrecognized tax benefits that would affect the effective tax rate	$ 691		$ 691		$ 671
Deferred tax asset, noncurrent	4,000		4,000
Deferred tax assets valuation allowance	1,474		1,474		$ 689
Undistributed earnings not permanently reinvested	100
Deferred tax on undistributed foreign earnings	1,000		1,000
PWS Settlement
Tax Credit Carryforward [Line Items]
Deferred tax assets	$ 3,200		$ 3,200

Earnings (Loss) Per Share (Deta

Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Earnings Per Share [Abstract]
Options outstanding not included in computation of diluted earnings per share (in shares)	33.1	36.9	32.9	36.5
Numerator:
Net income (loss) from continuing operations attributable to 3M	$ 1,204	$ (7,171)	$ 1,909	$ (6,509)
Net income (loss) from discontinued operations, net of taxes	(59)	330	164	644
Net income (loss) attributable to 3M	$ 1,145	$ (6,841)	$ 2,073	$ (5,865)
Denominator:
Denominator for weighted average 3M common shares outstanding - basic (in shares)	553.8	553.9	554.4	553.3
Dilution associated with stock-based compensation plans (in shares)	1	0	0.9	0
Denominator for weighted average 3M common shares outstanding – diluted (in shares)	554.8	553.9	555.3	553.3
Earnings (loss) per share from continuing operations — basic (in dollars per share)	$ 2.17	$ (12.94)	$ 3.44	$ (11.76)
Earnings (loss) per share from discontinued operations — basic (in dollars per share)	(0.10)	0.59	0.30	1.16
Earnings (loss) per share — basic (in dollars per share)	2.07	(12.35)	3.74	(10.60)
Earnings (loss) per share from continuing operations — diluted (in dollars per share)	2.17	(12.94)	3.44	(11.76)
Earnings (loss) per share from discontinued operations — diluted (in dollars per share)	(0.10)	0.59	0.29	1.16
Earnings (loss) per share — diluted (in dollars per share)	$ 2.07	$ (12.35)	$ 3.73	$ (10.60)

Marketable Securities - Current

Marketable Securities - Current and Non-current (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Debt Securities, Available-for-sale
Current marketable securities	$ 255	$ 50
Non-current marketable securities	34	20
Total marketable securities	289	70
Asset backed securities
Debt Securities, Available-for-sale
Current marketable securities	4	0
Non-current marketable securities	4	0
Foreign corporate debt
Debt Securities, Available-for-sale
Current marketable securities	6	0
U.S. government securities
Debt Securities, Available-for-sale
Current marketable securities	27	0
Corporate debt securities
Debt Securities, Available-for-sale
Current marketable securities	70	0
Non-current marketable securities	10	0
Commercial paper
Debt Securities, Available-for-sale
Current marketable securities	40	0
Certificates of deposit/time deposits
Debt Securities, Available-for-sale
Current marketable securities	91	46
U.S. treasury securities
Debt Securities, Available-for-sale
Current marketable securities	13	0
U.S. municipal securities
Debt Securities, Available-for-sale
Current marketable securities	4	4
Non-current marketable securities	$ 20	$ 20

Marketable Securities - Contrac

Marketable Securities - Contractual Maturity (Details) $ in Millions	Jun. 30, 2024 USD ($)
Marketable securities by contractual maturity
Due in one year or less	$ 255
Due after one year through five years	25
Due after five years through ten years	9
Total marketable securities	$ 289

Long-Term Debt and Short-Term_3

Long-Term Debt and Short-Term Borrowings - Narrative (Details) - USD ($)	1 Months Ended	3 Months Ended
	Feb. 29, 2024	Mar. 31, 2024	Jun. 30, 2024	Dec. 31, 2023
Debt instrument [Line Items]
Undrawn revolving credit facility		$ 2,000,000,000
Repayment of principal amount	$ 1,100,000,000
Solventum Notes Loans And Facilities
Debt instrument [Line Items]
Debt, aggregate principal amount		$ 8,400,000,000
Commercial paper
Debt instrument [Line Items]
Commercial paper outstanding			$ 0	$ 1,800,000,000

Long-Term Debt and Short-Term_4

Long-Term Debt and Short-Term Borrowings - Future Maturities of Long-term Debt (Details) $ in Millions	Jun. 30, 2024 USD ($)
Maturities of long-term debt
Remainder of 2024	$ 53
2025	1,868
2026	1,540
2027	847
2028	818
2029	1,790
After 2029	6,167
Total long-term debt	$ 13,083

Pension and Postretirement Be_3

Pension and Postretirement Benefit Plans - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2024	Apr. 01, 2024
Benefit Plan Information
Discontinued operation, pension plan benefit obligation				$ 2,700
Discontinued operation, postretirement plan benefit obligation				$ 2,400
Settlements, curtailments, special termination benefits and other	$ 795
Impact of remeasurement		$ 70	$ 220
U.S. Pension Plans
Benefit Plan Information
Company contributions			$ 81
Pension payment obligations transferred	$ 2,500
U.S. Pension Plans | United States
Benefit Plan Information
Discount rate	5.43%	5.22%	5.43%
Percentage increase (decrease) in discount rate obligation from the prior year		24%
U.S. Pension Plans | Minimum
Benefit Plan Information
Estimated pension contributions for current fiscal year	$ 100		$ 100
U.S. Pension Plans | Maximum
Benefit Plan Information
Estimated pension contributions for current fiscal year	$ 200		200
Postretirement Benefits
Benefit Plan Information
Company contributions			$ 5
Discount rate		5.19%
Percentage increase (decrease) in discount rate obligation from the prior year		25%

Pension and Postretirement Be_4

Pension and Postretirement Benefit Plans - Components of Net Periodic Benefit Cost and Other Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Non-operating expense
Total net periodic benefit cost (benefit)	$ 796	$ (25)	$ 785	$ (51)
Postretirement Benefits
Operating expense
Service cost	5	6	12	12
Non-operating expense
Interest cost	21	23	43	45
Expected return on plan assets	(15)	(19)	(34)	(38)
Amortization of transition asset	0	0	0	0
Amortization of prior service benefit	(6)	(8)	(12)	(16)
Amortization of net actuarial loss	4	2	10	4
Settlements, curtailments, special termination benefits and other	0	0	0	0
Total non-operating expense (benefit)	4	(2)	7	(5)
Total net periodic benefit cost (benefit)	9	4	19	7
Postretirement Benefits | Continuing Operations
Operating expense
Service cost	5	5	11	10
Non-operating expense
Total non-operating expense (benefit)	4	(2)	7	(4)
Total net periodic benefit cost (benefit)	9	3	18	6
Postretirement Benefits | Discontinued Operations
Operating expense
Service cost	0	1	1	2
Non-operating expense
Total non-operating expense (benefit)	0	0	0	(1)
Total net periodic benefit cost (benefit)	0	1	1	1
United States | U.S. Pension Plans
Operating expense
Service cost	29	43	66	86
Non-operating expense
Interest cost	141	165	301	331
Expected return on plan assets	(196)	(244)	(433)	(488)
Amortization of transition asset	0	0	0	0
Amortization of prior service benefit	(4)	(6)	(8)	(12)
Amortization of net actuarial loss	83	74	178	147
Settlements, curtailments, special termination benefits and other	795	0	795	0
Total non-operating expense (benefit)	819	(11)	833	(22)
Total net periodic benefit cost (benefit)	848	32	899	64
United States | U.S. Pension Plans | Continuing Operations
Operating expense
Service cost	29	35	59	70
Non-operating expense
Total non-operating expense (benefit)	819	(7)	833	(14)
Total net periodic benefit cost (benefit)	848	28	892	56
United States | U.S. Pension Plans | Discontinued Operations
Operating expense
Service cost	0	8	7	16
Non-operating expense
Total non-operating expense (benefit)	0	(4)	0	(8)
Total net periodic benefit cost (benefit)	0	4	7	8
International | U.S. Pension Plans
Operating expense
Service cost	14	20	35	39
Non-operating expense
Interest cost	49	54	103	109
Expected return on plan assets	(80)	(75)	(167)	(150)
Amortization of transition asset	1	1	2	1
Amortization of prior service benefit	0	0	1	1
Amortization of net actuarial loss	3	2	6	4
Settlements, curtailments, special termination benefits and other	0	0	0	0
Total non-operating expense (benefit)	(27)	(18)	(55)	(35)
Total net periodic benefit cost (benefit)	(13)	2	(20)	4
International | U.S. Pension Plans | Continuing Operations
Operating expense
Service cost	14	16	30	31
Non-operating expense
Total non-operating expense (benefit)	(27)	(16)	(55)	(33)
Total net periodic benefit cost (benefit)	(13)	0	(25)	(2)
International | U.S. Pension Plans | Discontinued Operations
Operating expense
Service cost	0	4	5	8
Non-operating expense
Total non-operating expense (benefit)	0	(2)	0	(2)
Total net periodic benefit cost (benefit)	$ 0	$ 2	$ 5	$ 6

Supplier Finance Program Obli_2

Supplier Finance Program Obligations (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Outstanding balances of confirmed invoices	$ 320	$ 270
Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]	Accounts payable	Accounts payable

Derivatives - Cash Flow Hedges

Derivatives - Cash Flow Hedges (Details) - Cash flow hedge $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($)
Derivatives in Cash Flow Hedging Relationships
Accumulated other comprehensive income (loss), unrealized gain (loss) on cash flow hedges	$ (35)
After-tax net unrealized gain (loss) anticipated to be reclassified from AOCI to the income statement within next twelve months	38
Interest rate swap and treasury lock in aggregate
Derivatives in Cash Flow Hedging Relationships
Accumulated other comprehensive income (loss), unrealized gain (loss) on cash flow hedges	$ (83)

Derivatives - Cash Flow Hedge_2

Derivatives - Cash Flow Hedges - Gain (Loss) in OCI or Reclassified from AOCI (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Cash flow hedge | Foreign currency forward/option contracts
Derivatives in Cash Flow Hedging Relationships
Foreign currency forward/option contracts	$ 23	$ 72	$ 84	$ 78

Derivatives - Cumulative Basis

Derivatives - Cumulative Basis Adjustment for Fair Value Hedges (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Location and Fair Value Amount of Derivative Instruments
Hedged Liability, Statement of Financial Position [Extensible Enumeration]	Long-term debt	Long-term debt
Fair value hedges
Location and Fair Value Amount of Derivative Instruments
Carrying Value of the Hedged Liabilities	$ 909	$ 918
Fair value hedges | Long-term debt
Location and Fair Value Amount of Derivative Instruments
Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Value of the Hedged Liabilities	$ (93)	$ (84)

Derivatives - Net Investment He

Derivatives - Net Investment Hedges (Details) - Net Investment Hedges € in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 EUR (€)
Net investment hedges
Effective portion of net investment hedge reclassified out of other comprehensive income into income			$ 0	$ 0
Total	$ 15,000,000	$ (23,000,000)	61,000,000	(68,000,000)
Foreign currency forward contracts
Net investment hedges
Derivative, notional amount | €					€ 150
Total	2,000,000	(1,000,000)	5,000,000	(3,000,000)
Foreign currency denominated debt
Net investment hedges
Face amount of debt designated as a net investment hedge (in euros) | €					€ 1,800
Total	$ 13,000,000	$ (22,000,000)	$ 56,000,000	$ (65,000,000)

Derivatives - Income Location a

Derivatives - Income Location and Impact of Cash Flow (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Cost of sales
Information regarding cash flow and fair value hedging relationships:
Total consolidated financial statement line item amount	$ 3,571	$ 3,728	$ 7,056	$ 7,472
Other expense (income), net
Information regarding cash flow and fair value hedging relationships:
Total consolidated financial statement line item amount	(138)	72	82	128
Foreign currency forward/option contracts | Derivatives not designated as hedging instruments | Cost of sales
Information regarding derivatives not designated as hedging instruments:
Foreign currency forward/option contracts	2	13	7	5
Foreign currency forward/option contracts | Derivatives not designated as hedging instruments | Other expense (income), net
Information regarding derivatives not designated as hedging instruments:
Foreign currency forward/option contracts	4	(39)	6	(13)
Cash flow hedge | Foreign currency forward/option contracts | Cost of sales
(Gain) or loss on cash flow hedging relationships:
Amount of (gain) or loss reclassified from accumulated other comprehensive income (loss) into income	(32)	(42)	(61)	(85)
Cash flow hedge | Foreign currency forward/option contracts | Other expense (income), net
(Gain) or loss on cash flow hedging relationships:
Amount of (gain) or loss reclassified from accumulated other comprehensive income (loss) into income	0	0	0	0
Cash flow hedge | Interest rate contracts | Cost of sales
(Gain) or loss on cash flow hedging relationships:
Amount of (gain) or loss reclassified from accumulated other comprehensive income (loss) into income	0	0	0	0
Cash flow hedge | Interest rate contracts | Other expense (income), net
(Gain) or loss on cash flow hedging relationships:
Amount of (gain) or loss reclassified from accumulated other comprehensive income (loss) into income	2	2	4	4
Fair value hedges | Interest rate contracts | Cost of sales
(Gain) or loss on fair value hedging relationships:
Hedged items	0	0	0	0
Fair value hedges | Interest rate contracts | Other expense (income), net
(Gain) or loss on fair value hedging relationships:
Hedged items	2	(9)	(9)	3
Fair value hedges | Interest rate contracts | Derivatives designated as hedging instruments | Cost of sales
(Gain) or loss on fair value hedging relationships:
Derivatives designated as hedging instruments	0	0	0	0
Fair value hedges | Interest rate contracts | Derivatives designated as hedging instruments | Other expense (income), net
(Gain) or loss on fair value hedging relationships:
Derivatives designated as hedging instruments	$ (2)	$ 9	$ 9	$ (3)

Derivatives - Balance Sheet Loc

Derivatives - Balance Sheet Location (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Location and Fair Value Amount of Derivative Instruments
Derivative assets, fair value	$ 86	$ 84
Derivative liability, fair value	107	127
Derivatives designated as hedging instruments
Location and Fair Value Amount of Derivative Instruments
Derivative assets, fair value	86	79
Derivative liability, fair value	106	120
Derivatives designated as hedging instruments | Foreign currency forward/option contracts | Current Balance Sheet Location
Location and Fair Value Amount of Derivative Instruments
Gross Notional Amount	1,821	2,109
Derivatives designated as hedging instruments | Foreign currency forward/option contracts | Noncurrent balance sheet location
Location and Fair Value Amount of Derivative Instruments
Gross Notional Amount	725	342
Derivatives designated as hedging instruments | Foreign currency forward/option contracts | Other current assets
Location and Fair Value Amount of Derivative Instruments
Derivative assets, fair value	74	68
Derivatives designated as hedging instruments | Foreign currency forward/option contracts | Other assets
Location and Fair Value Amount of Derivative Instruments
Derivative assets, fair value	12	11
Derivatives designated as hedging instruments | Foreign currency forward/option contracts | Other current liabilities
Location and Fair Value Amount of Derivative Instruments
Derivative liability, fair value	5	27
Derivatives designated as hedging instruments | Foreign currency forward/option contracts | Other liabilities
Location and Fair Value Amount of Derivative Instruments
Derivative liability, fair value	5	5
Derivatives designated as hedging instruments | Interest rate contracts | Noncurrent balance sheet location
Location and Fair Value Amount of Derivative Instruments
Gross Notional Amount	800	800
Derivatives designated as hedging instruments | Interest rate contracts | Other assets
Location and Fair Value Amount of Derivative Instruments
Derivative assets, fair value	0	0
Derivatives designated as hedging instruments | Interest rate contracts | Other liabilities
Location and Fair Value Amount of Derivative Instruments
Derivative liability, fair value	96	88
Derivatives not designated as hedging instruments
Location and Fair Value Amount of Derivative Instruments
Derivative assets, fair value	0	5
Derivative liability, fair value	1	7
Derivatives not designated as hedging instruments | Foreign currency forward/option contracts | Current Balance Sheet Location
Location and Fair Value Amount of Derivative Instruments
Gross Notional Amount	659	1,023
Derivatives not designated as hedging instruments | Foreign currency forward/option contracts | Other current assets
Location and Fair Value Amount of Derivative Instruments
Derivative assets, fair value	0	5
Derivatives not designated as hedging instruments | Foreign currency forward/option contracts | Other current liabilities
Location and Fair Value Amount of Derivative Instruments
Derivative liability, fair value	$ 1	$ 7

Derivatives - Currency Effects

Derivatives - Currency Effects (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Foreign Currency [Abstract]
Year-on-year foreign currency transaction effects, including hedging impact, increase (decrease) impact on pre-tax (loss) income	$ 2	$ (32)	$ (19)	$ (62)

Fair Value Measurements - Recur

Fair Value Measurements - Recurring Basis (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	$ 289	$ 70
Derivative assets, fair value	86	84
Fair value on a recurring basis
Assets and Liabilities Measured on Recurring Basis
Solventum common stock	1,817	0
Fair value on a recurring basis | Foreign currency forward/option contracts
Assets and Liabilities Measured on Recurring Basis
Derivative assets, fair value	86	84
Derivative liability, fair value	11	39
Fair value on a recurring basis | Interest rate contracts
Assets and Liabilities Measured on Recurring Basis
Derivative liability, fair value	96	88
Fair value on a recurring basis | Asset backed securities
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	8	0
Fair value on a recurring basis | Foreign corporate debt
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	6	0
Fair value on a recurring basis | U.S. government securities
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	27	0
Fair value on a recurring basis | Corporate debt securities
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	80	0
Fair value on a recurring basis | Commercial paper
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	40	0
Fair value on a recurring basis | Certificates of deposit/time deposits
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	91	46
Fair value on a recurring basis | U.S. treasury securities
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	13	0
Fair value on a recurring basis | U.S. municipal securities
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	24	24
Fair value on a recurring basis | Level 1
Assets and Liabilities Measured on Recurring Basis
Solventum common stock	1,817	0
Fair value on a recurring basis | Level 1 | Foreign currency forward/option contracts
Assets and Liabilities Measured on Recurring Basis
Derivative assets, fair value	0	0
Derivative liability, fair value	0	0
Fair value on a recurring basis | Level 1 | Interest rate contracts
Assets and Liabilities Measured on Recurring Basis
Derivative liability, fair value	0	0
Fair value on a recurring basis | Level 1 | Asset backed securities
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	0	0
Fair value on a recurring basis | Level 1 | Foreign corporate debt
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	0	0
Fair value on a recurring basis | Level 1 | U.S. government securities
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	27	0
Fair value on a recurring basis | Level 1 | Corporate debt securities
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	0	0
Fair value on a recurring basis | Level 1 | Commercial paper
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	0	0
Fair value on a recurring basis | Level 1 | Certificates of deposit/time deposits
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	0	0
Fair value on a recurring basis | Level 1 | U.S. treasury securities
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	13	0
Fair value on a recurring basis | Level 1 | U.S. municipal securities
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	0	0
Fair value on a recurring basis | Level 2
Assets and Liabilities Measured on Recurring Basis
Solventum common stock	0	0
Fair value on a recurring basis | Level 2 | Foreign currency forward/option contracts
Assets and Liabilities Measured on Recurring Basis
Derivative assets, fair value	86	84
Derivative liability, fair value	11	39
Fair value on a recurring basis | Level 2 | Interest rate contracts
Assets and Liabilities Measured on Recurring Basis
Derivative liability, fair value	96	88
Fair value on a recurring basis | Level 2 | Asset backed securities
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	8	0
Fair value on a recurring basis | Level 2 | Foreign corporate debt
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	6	0
Fair value on a recurring basis | Level 2 | U.S. government securities
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	0	0
Fair value on a recurring basis | Level 2 | Corporate debt securities
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	80	0
Fair value on a recurring basis | Level 2 | Commercial paper
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	40	0
Fair value on a recurring basis | Level 2 | Certificates of deposit/time deposits
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	91	46
Fair value on a recurring basis | Level 2 | U.S. treasury securities
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	0	0
Fair value on a recurring basis | Level 2 | U.S. municipal securities
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	0	0
Fair value on a recurring basis | Level 3
Assets and Liabilities Measured on Recurring Basis
Solventum common stock	0	0
Fair value on a recurring basis | Level 3 | Foreign currency forward/option contracts
Assets and Liabilities Measured on Recurring Basis
Derivative assets, fair value	0	0
Derivative liability, fair value	0	0
Fair value on a recurring basis | Level 3 | Interest rate contracts
Assets and Liabilities Measured on Recurring Basis
Derivative liability, fair value	0	0
Fair value on a recurring basis | Level 3 | Asset backed securities
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	0	0
Fair value on a recurring basis | Level 3 | Foreign corporate debt
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	0	0
Fair value on a recurring basis | Level 3 | U.S. government securities
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	0	0
Fair value on a recurring basis | Level 3 | Corporate debt securities
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	0	0
Fair value on a recurring basis | Level 3 | Commercial paper
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	0	0
Fair value on a recurring basis | Level 3 | Certificates of deposit/time deposits
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	0	0
Fair value on a recurring basis | Level 3 | U.S. treasury securities
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	0	0
Fair value on a recurring basis | Level 3 | U.S. municipal securities
Assets and Liabilities Measured on Recurring Basis
Available-for-sale marketable securities	$ 24	$ 24

Fair Value Measurements - Finan

Fair Value Measurements - Financial Instruments (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Carrying Value
Financial Instruments
Long-term debt, excluding current portion	$ 11,781	$ 13,088
Fair Value
Financial Instruments
Long-term debt, excluding current portion	$ 10,374	$ 11,859

Commitments and Contingencies -

Commitments and Contingencies - Respirator (Details) respirator in Millions	1 Months Ended		3 Months Ended	6 Months Ended					12 Months Ended
	Oct. 31, 2019 USD ($) respirator	Apr. 30, 2018 USD ($) plaintiff	Mar. 31, 2024 plaintiff	Jun. 30, 2024 USD ($) party	Jun. 30, 2024 USD ($) party plaintiff	Jun. 30, 2024 USD ($) party case	Jun. 30, 2024 USD ($) party lawsuit	Jun. 30, 2024 USD ($) party	Dec. 31, 2019 USD ($)	Dec. 31, 2018 lawsuit
Respirator Mask/Asbestos Litigation
Loss contingencies
Total number of named claimants | plaintiff			4,060		4,106
Number of years company has been the defendant in Respirator Mask/Asbestos Litigation				20 years
Number of total claims the Company prevailed after being taken to trial						17	18			2
Accrued loss contingency reserve				$ 552,000,000	$ 552,000,000	$ 552,000,000	$ 552,000,000	$ 552,000,000
Increase (decrease) accrued loss contingency reserve								19,000,000
Payments for fees and settlements related to litigation								41,000,000
Insurance receivables				$ 0	$ 0	$ 0	$ 0	$ 0
Respirator Mask/Asbestos Litigation | Class Action Fairness Act
Loss contingencies
Total number of named claimants | plaintiff					400
Number of lawsuits filed | case						2
Respirator Mask/Asbestos Litigation | State court of California
Loss contingencies
Number of total claims the Company prevailed after being taken to trial | lawsuit										1
Respirator Mask/Asbestos Litigation | State court of Kentucky
Loss contingencies
Number of unnamed defendant | plaintiff		2
Litigation settlement awarded		$ 2,000,000
Amount of punitive damages awarded		$ 63,000,000
Respirator Mask/Asbestos Litigation | Kentucky and West Virginia
Loss contingencies
Settlement amount paid									$ 340,000,000
Respirator Mask/Asbestos Litigation - State of West Virginia
Loss contingencies
Amount of punitive damages awarded	$ 5,000
Number of additional defendants | party				2	2	2	2	2
Number of respirators sold | respirator	5
Accrued loss contingency reserve				$ 0	$ 0	$ 0	$ 0	$ 0
Respirator Mask/Asbestos Litigation - Aearo Technologies
Loss contingencies
Accrued loss contingency reserve				$ 53,000,000	$ 53,000,000	$ 53,000,000	$ 53,000,000	53,000,000
Quarterly fee paid to Cabot to retain responsibility and liability for products								$ 100,000

Commitments and Contingencies_2

Commitments and Contingencies - Environmental (Details)	1 Months Ended																3 Months Ended	6 Months Ended		7 Months Ended
	Jul. 31, 2024 case	Mar. 31, 2024 plaintiff	Feb. 29, 2024 lawsuit	Jan. 31, 2024 lawsuit	Dec. 31, 2023 plaintiff case	Oct. 31, 2023 lawsuit	Aug. 31, 2023 lawsuit	May 31, 2023 EUR (€) party action	Mar. 31, 2023 party	Dec. 31, 2022 action	Jul. 31, 2022 EUR (€)	Jun. 30, 2020 lawsuit	Jun. 30, 2019 lawsuit	May 31, 2019 lawsuit	Mar. 31, 2019 facility lawsuit	Jul. 31, 2018 USD ($) defendant chemical facility mi	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) lawsuit case perfluorinated_material party	Jun. 30, 2022 USD ($)	Jun. 30, 2024 USD ($) lawsuit plaintiff party	Jun. 30, 2024 USD ($) lawsuit case party	Jun. 30, 2024 USD ($) lawsuit injury party
Product Liability Litigation
Number of actions taken from lawsuits | action										2
Increase in liabilities, gross											€ 571,000,000								$ 500,000,000
Belgian Civil Litigation
Product Liability Litigation
Number of lawsuits pending | party																		17		17	17	17
Number of cases settled | action								1
Settlement amount paid | €								€ 500
Number of family members awarded | party								4
Total number of named claimants | plaintiff					1,400
City of Muscle Shoals, Alabama vs. 3M | Pending Litigation
Product Liability Litigation
Total number of named claimants | plaintiff																				29
Number of personal injury actions against 3M																					9	9
Number of cases transferred to MDL | case																					7
Number of cases pending transfer | case																					2
PFAS Contamination
Product Liability Litigation
Number of lawsuits filed			2	2		2	2	2	2
PWS Settlement | Pending Litigation
Product Liability Litigation
Total number of named claimants | plaintiff		25			25
Estimate of possible settlement amount | $																		$ 12,500,000,000		$ 12,500,000,000	$ 12,500,000,000	$ 12,500,000,000
Pre-tax charge on settlement | $																	$ 10,300,000,000
Present value of possible loss																		5.20%		5.20%	5.20%	5.20%
Number of cases | case					25
PWS Settlement | Pending Litigation | Subsequent Event
Product Liability Litigation
Number of cases to undergo further discovery | case	9
PWS Settlement | Pending Litigation | Minimum
Product Liability Litigation
Estimate of possible settlement amount | $																		$ 10,500,000,000		$ 10,500,000,000	$ 10,500,000,000	$ 10,500,000,000
PWS Settlement | Pending Litigation | Maximum
Product Liability Litigation
Estimate of possible settlement amount | $																		$ 12,500,000,000		$ 12,500,000,000	$ 12,500,000,000	$ 12,500,000,000
Environmental Matters - Regulatory Activities
Product Liability Litigation
Number of years after phase-out decision in May 2000 that the Company stopped manufacturing and using vast majority of perfluorooctanyl compounds																		2 years
Environmental Matters - Litigation | New Jersey
Product Liability Litigation
Number of lawsuits filed												2			2
Number of additional new claims filed												2
Environmental Matters - Litigation | Salem County, New Jersey
Product Liability Litigation
Number of facilities related to the manufacture and disposal of PFAS | facility															2
Environmental Matters - Litigation | New Hampshire
Product Liability Litigation
Number of cases transferred to MDL														1
Number of lawsuits filed														2
Environmental Matters - Litigation | Vermont
Product Liability Litigation
Number of cases transferred to MDL													1
Number of lawsuits filed													2
Environmental Matters - Litigation | Illinois
Product Liability Litigation
Number of lawsuits filed													2
Environmental Matters - Aqueous Film Forming Foam Litigation
Product Liability Litigation
Number of putative class action and other lawsuits																		9,017
Number of class action lawsuits																		49
Number of public water system lawsuits																		741		741	741	741
Number of pre-suits																		1
Environmental Matters - Aqueous Film Forming Foam Litigation | Various state courts
Product Liability Litigation
Number of lawsuits pending																		5		5	5	5
Number of lawsuits filed													8
Environmental Matters - Aqueous Film Forming Foam Litigation | Federal court
Product Liability Litigation
Number of lawsuits pending																		2		2	2	2
Claims dismissed																		1
Environmental Matters - Other PFAS-related Environmental Litigation
Product Liability Litigation
Increase (decrease) accrued loss contingency reserve | $																		$ 400,000,000
Litigation payments | $																		$ 100,000,000
Environmental Matters - Other PFAS-related Environmental Litigation | New Jersey
Product Liability Litigation
Number of lawsuits filed																		28
Number of lawsuits seeking medical monitoring and damages | case																		10
Environmental Matters - Other PFAS-related Environmental Litigation | Alabama and Georgia
Product Liability Litigation
Number of putative class action and other lawsuits																		5
Environmental Matters - Other PFAS-related Environmental Litigation | Delaware.
Product Liability Litigation
Number of putative class action and other lawsuits																		1
Environmental Matters - Other PFAS-related Environmental Litigation | Decatur, Alabama
Product Liability Litigation
Number of perfluorinated materials (FBSA and FBSEE) | perfluorinated_material																		2
Environmental Matters Other Pfc Related Environmental Litigation, Individual Cases | New Jersey
Product Liability Litigation
Number of lawsuits filed																		18
Environmental Matters - Other Environmental Litigation
Product Liability Litigation
Accrued loss contingency reserve | $																		$ 11,300,000,000		$ 11,300,000,000	$ 11,300,000,000	$ 11,300,000,000
Environmental Matters - Other Environmental Litigation | Other current liabilities
Product Liability Litigation
Accrued loss contingency reserve | $																		4,800,000,000		4,800,000,000	4,800,000,000	4,800,000,000
Environmental Matters - Other Environmental Litigation | Other liabilities
Product Liability Litigation
Accrued loss contingency reserve | $																		6,500,000,000		6,500,000,000	6,500,000,000	6,500,000,000
Environmental Matters - Other Environmental Litigation | New Jersey
Product Liability Litigation
Approximate number of miles of a river seeking to be cleaned | mi																8
The value the award the plaintiff seeks | $																$ 165,000,000
Number of chemicals of concern in the sediment | chemical																8
Number of commercial drum conditioning facilities | facility																2
Environmental Matters - Other Environmental Litigation | New Jersey | Minimum
Product Liability Litigation
Number of unnamed defendant | defendant																120
Environmental Matters - Other
Product Liability Litigation
Accrued loss contingency reserve | $																		0		0	0	0
Environmental Matters - Remediation
Product Liability Litigation
Accrued loss contingency reserve | $																		$ 35,000,000		$ 35,000,000	$ 35,000,000	$ 35,000,000
Number of years remediation payments expected to be paid for applicable sites																		20 years

Commitments and Contingencies_3

Commitments and Contingencies - Product Liability (Details) $ in Millions

1 Months Ended

3 Months Ended

6 Months Ended

Jul. 15, 2024 USD ($)

Apr. 15, 2024 USD ($)

Jan. 31, 2024 USD ($)

Jul. 31, 2024 motion

Dec. 31, 2023 USD ($)

Sep. 30, 2023 USD ($) bellwetherPlaintiff

Aug. 31, 2023 USD ($)

Dec. 31, 2020 plaintiff

Sep. 30, 2023 USD ($)

Jun. 30, 2022 USD ($)

Jun. 30, 2024 USD ($)

Mar. 26, 2024 claim

Jul. 31, 2022 USD ($)

Product Liability Litigation

Payments in common stock

$ 1,000

Environmental Matters - Other PFAS-related Environmental Litigation

Product Liability Litigation

Litigation payments

$ 100

Increase (decrease) accrued loss contingency reserve

400

Product Liability - Dual-Ended Combat Arms Earplugs

Product Liability Litigation

Committed amount to product liability accrual

$ 1,000

Pre-tax charge on product liability

$ 1,200

Product Liability - Dual-Ended Combat Arms Earplugs | Additional Projected Case Expenses

Product Liability Litigation

Committed amount to product liability accrual

$ 200

Product Liability - Dual-Ended Combat Arms Earplugs | Multi-district litigation (MDL)

Product Liability Litigation

Total number of named claimants | plaintiff

3

CAE Settlement

Product Liability Litigation

Loss contingency, receivable

51

Insurance receivables

72

CAE Settlement | Subsequent Event

Product Liability Litigation

Motions granted | motion

1

CAE Settlement | Settled Litigation

Product Liability Litigation

Pre-tax charge on product liability

$ 4,200

Settlement amount paid

$ 6,000

Percentage of individuals with potential litigation claims enrolled

98%

Cash consideration

$ 5,000

Payments in common stock

1,000

Accrual, net

$ 5,300

$ 1,100

$ 5,300

Estimated discount interest rate

5.60%

Litigation payments

$ 350

$ 250

10

Payments for fees and settlements related to litigation

$ 147

Number of bellwether plaintiffs | bellwetherPlaintiff

13

Payments for additional settlements

$ 253

Participating claimants in settlement (as a percentage)

99.90%

Number of participating claims | claim

293,000

Number of registers claimants | claim

251,000

Number of claimants dismissed | claim

41,000

Participation threshold (as a percent)

98%

Accrued loss contingency reserve

4,500

CAE Settlement | Settled Litigation | Subsequent Event

Product Liability Litigation

Litigation payments

$ 750

CAE Settlement | Settled Litigation | Other current liabilities

Product Liability Litigation

Accrued loss contingency reserve

2,200

CAE Settlement | Settled Litigation | Other liabilities

Product Liability Litigation

Accrued loss contingency reserve

2,300

CAE Settlement | Environmental Matters - Other PFAS-related Environmental Litigation

Product Liability Litigation

Litigation payments

600

Increase (decrease) accrued loss contingency reserve

$ 100

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details)	6 Months Ended
	Jun. 30, 2024 age
Share-Based Payment Arrangement [Abstract]
Retirement age eligibility for employees	55
Retirement eligibility for employees, minimum years of service required (in years)	10 years
Percent of stock-based compensation related to retiree-eligible population (as a percent)	34%

Stock-Based Compensation - Comp

Stock-Based Compensation - Compensation (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Amounts recognized in the financial statements
Stock-based compensation expenses	$ 154	$ 35	$ 180	$ 155
Income tax benefits	(33)	(4)	(14)	(28)
Stock-based compensation expenses (benefits), net of tax	121	31	166	127
Cost of sales
Amounts recognized in the financial statements
Stock-based compensation expenses	19	8	24	26
Selling, general and administrative expenses
Amounts recognized in the financial statements
Stock-based compensation expenses	107	21	125	100
Research, development and related expenses
Amounts recognized in the financial statements
Stock-based compensation expenses	$ 28	$ 6	$ 31	$ 29

Business Segments - Narrative (

Business Segments - Narrative (Details)	6 Months Ended
	Jun. 30, 2024 division segment
Segment Reporting [Abstract]
Number of business segments | segment	3
Number of divisions | division	4

Business Segments - Schedule of

Business Segments - Schedule of Business Segment Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Business Segment Information
Net sales	$ 6,255	$ 6,283	$ 12,271	$ 12,338
Total Company operating income (loss)	1,272	(9,358)	2,421	(8,492)
Total operating expenses	4,983	15,641	9,850	20,830
Other expense (income), net	(138)	72	82	128
Income (loss) from continuing operations before income taxes	1,410	(9,430)	2,339	(8,620)
Operating Segments
Business Segment Information
Net sales	4	12	18	23
Operating Segments | Safety and Industrial
Business Segment Information
Net sales	2,759	2,765	5,491	5,544
Total Company operating income (loss)	612	534	1,269	1,135
Operating Segments | Transportation and Electronics
Business Segment Information
Net sales	2,143	2,191	4,247	4,241
Total Company operating income (loss)	428	410	909	704
Operating Segments | Consumer
Business Segment Information
Net sales	1,263	1,293	2,403	2,485
Total Company operating income (loss)	219	235	435	414
Corporate and Unallocated
Business Segment Information
Net sales	86	22	112	45
Net costs for significant litigation	(8)	(10,357)	(71)	(10,439)
Divestiture costs	(14)	(1)	(20)	(4)
Russia exit (charges) benefits	0	18	0	18
Total corporate special items	(22)	(10,340)	(91)	(10,425)
Other corporate (expense) income - net	(2)	(207)	(73)	(339)
Total operating expenses	(24)	(10,547)	(164)	(10,764)
Other
Business Segment Information
Total Company operating income (loss)	$ 37	$ 10	$ (28)	$ 19